Any feedback?
Information on EC 1.1.1.34 - hydroxymethylglutaryl-CoA reductase (NADPH) and Organism(s) Homo sapiens
for references in articles please use BRENDA:EC1.1.1.34Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH)IUBMB Comments
The enzyme is inactivated by EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} and reactivated by EC 3.1.3.47 {[hydroxymethylglutaryl-CoA reductase (NADPH)]-phosphatase}.
Specify your search results
Word Map
- 1.1.1.34
- cholesterol
- statin
- lipoprotein
- simvastatin
- sterol
- cardiovascular
- triglyceride
-
low-density
- hypercholesterolemia
- lovastatin
- pravastatin
- coronary
-
lipid-lowering
- bile
- endothelial
- artery
- atorvastatin
- atherosclerosis
-
isoprenoids
- hdl
-
cholesterol-lowering
- hyperlipidemia
-
ldl-cholesterol
-
placebo
- squalene
-
apolipoproteins
- myopathy
-
hypocholesterolemic
-
farnesylation
-
geranylgeranylation
-
hypolipidemic
- rosuvastatin
- dyslipidemias
-
high-density
-
fibrates
- cyp7a1
- cholestyramine
- rhabdomyolysis
-
7alpha-hydroxylase
- drug development
- medicine
- nutrition
-
acyl-coa:cholesterol
- molecular biology
- 25-hydroxycholesterol
- lanosterol
- gemfibrozil
- pcsk9
- ezetimibe
- biotechnology
- dolichols
-
isoprenylation
- srebp-2
-
statin-induced
-
lipoprotein-cholesterol
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
The enzyme appears in selected viruses and cellular organisms
Reaction Schemes
+
+
2
=
+
2
+
2
Synonyms
hmg-coa reductase, hmgcr, 3-hydroxy-3-methylglutaryl coenzyme a reductase, hmgr, hmg coa reductase, 3-hydroxy-3-methylglutaryl-coa reductase, 3-hydroxy-3-methylglutaryl-coenzyme a reductase, hmgcoa reductase, 3-hydroxy-3-methylglutaryl coa reductase, hmg-coar, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
3-hydroxy-3-methylglutaryl-CoA reductase
3-hydroxy-3-methylglutaryl-CoA reductase (NADPH)
-
-
-
-
beta-hydroxy-beta-methylglutaryl coenzyme A reductase
-
-
-
-
beta-hydroxy-beta-methylglutaryl-Co A reductase
-
-
-
-
HMG-CoA reductase
HMG2.2
-
-
-
-
HMG3.3
-
-
-
-
HMGCoA reductase-mevalonate:NADP-oxidoreductase (acetylating CoA)
-
-
-
-
HMGCR
HMGR
HMGR1
-
-
-
-
HMGR2
-
-
-
-
hydroxymethylglutaryl CoA reductase (NADPH)
-
-
-
-
hydroxymethylglutaryl-coenzyme A reductase (reduced nicotinamide adenine dinucleotide phosphate)
-
-
-
-
mevalonate:NADP+ oxidoreductase (acetylating CoA)
-
-
-
-
NADPH-hydroxymethylglutaryl-CoA reductase
-
-
-
-
S-3-hydroxy-3-methylglutaryl-CoA reductase
-
-
-
-
3-hydroxy-3-methylglutaryl-CoA reductase
-
-
-
-
HMG-CoA reductase
-
-
-
-
HMGR
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
(R)-mevalonate + CoA + 2 NADP+ = (S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
Glu559 and His866 are involved in catalysis
-
(R)-mevalonate + CoA + 2 NADP+ = (S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
reaction mechanism, modelling of three different systems, detailed overview. Formation of a mevaldyl-CoA intermediate protonated by a conserved active site lysine, Lys691. The conserved active site glutamate and aspartate residues, Glu559 and Asp767, along with the ribose moiety of NADPH, form a hydrogen bond network crucial to the increase of the stabilizing effect of Lys691 over the transition state. A charged His752 forms an oxyanion hole with Lys691 to stabilize the negative charge developed in the thioester oxygen
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
-
-, -, -, -, -
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
(R)-mevalonate:NADP+ oxidoreductase (CoA-acylating)
The enzyme is inactivated by EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} and reactivated by EC 3.1.3.47 {[hydroxymethylglutaryl-CoA reductase (NADPH)]-phosphatase}.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9028-35-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(S)-3-hydroxy-3-methylglutaryl-CoA + NADPH + H+
mevaldyl-CoA + NADP+
-
first step reaction
-
-
?
3-hydroxy-3-methylglutaryl-CoA + NADPH
(R)-mevalonate + CoA + NADP+
-
-
-
-
?
mevaldyl-CoA + NADPH + H+ + H2O
(R)-mevalonate + CoA + NADP+
-
second step reaction
-
-
?
(R)-mevalonate + CoA + 2 NADP+
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
-
-
-
r
(R)-mevalonate + CoA + 2 NADP+
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
-
-
-
-
r
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
(R)-mevalonate + CoA + 2 NADP+
-
-
-
-
?
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
(R)-mevalonate + CoA + 2 NADP+
-
-
-
-
r
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
(R)-mevalonate + CoA + 2 NADP+
-
-
-
r
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
mevalonate + CoA + 2 NADP+
-
-
-
-
r
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
mevalonate + CoA + 2 NADP+
-
-
-
r
additional information
?
-
-
the reaction is a highly regulated process within the cholesterol biosynthetic pathway
-
-
?
additional information
?
-
-
method development for rapid and versatile reverse phase -HPLC monitoring for assaying HMGR activity capable of monitoring the levels of both substrates HMG-CoA and NADPH, and products CoA, mevalonate, and NADP+, method evaluation, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(S)-3-hydroxy-3-methylglutaryl-CoA + NADPH + H+
mevaldyl-CoA + NADP+
-
first step reaction
-
-
?
3-hydroxy-3-methylglutaryl-CoA + NADPH
(R)-mevalonate + CoA + NADP+
-
-
-
-
?
mevaldyl-CoA + NADPH + H+ + H2O
(R)-mevalonate + CoA + NADP+
-
second step reaction
-
-
?
additional information
?
-
-
the reaction is a highly regulated process within the cholesterol biosynthetic pathway
-
-
?
(R)-mevalonate + CoA + 2 NADP+
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
-
-
-
r
(R)-mevalonate + CoA + 2 NADP+
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
-
-
-
-
r
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
(R)-mevalonate + CoA + 2 NADP+
-
-
-
-
?
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
(R)-mevalonate + CoA + 2 NADP+
-
-
-
-
r
(S)-3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
(R)-mevalonate + CoA + 2 NADP+
-
-
-
r
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
mevalonate + CoA + 2 NADP+
-
-
-
-
r
3-hydroxy-3-methylglutaryl-CoA + 2 NADPH + 2 H+
mevalonate + CoA + 2 NADP+
-
-
-
r
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
brutieridin
i.e. hesperetin 7-(2''-alpha-rhamnosyl-6''-(3''''-hydroxy-3''''-methylglutaryl)-beta-D-glucoside), a flavonoid conjugate from bergamot fruit extract, structural analogue of statins, computational study, overview
ceramide
-
treatment with exogenous ceramides, or increasing the endogenous ceramide levels inhibits HMGCR by 6080%
cycloheximide
-
downregulation of protein synthesis, synergistic with eicosapentanoic acid and myristic acid
eicosapentaenoic acid
-
inhibits translation of the enzyme about 50% at 0.15 mM, downregulation, slightly increases downregulation of protein synthesis by cycloheximide
melitidin
i.e. naringenin 7-(2''-alpha-rhamnosyl-6''-(3''''-hydroxy-3''''-methylglutaryl)-beta-D-glucoside), a flavonoid conjugate from bergamot fruit extract, structural analogue of statins, computational study, overview
SFGYVAE peptide
-
most active inhibitory peptide; shows high ability to inhibit HMGR by competitive inhibition with respect to (S)-3-hydroxy-3-methylglutaryl-CoA
SMase C
-
treatment of fibroblasts with SMase C results in a 90% inhibition of HMGCR
-
atorvastatin
-
has a differentiating effect on wild-type and mutant forms of the human protein
fluvastatin
-
has a differentiating effect on wild-type and mutant forms of the human protein
pravastatin
inhibitory in the presence of increasing concentrations of NADPH, but increasing concentrations of HMG-CoA block the HMG-CoA reductase-inhibiting activity
rosuvastatin
-
thermodynamics of binding and inhibition mechanism, Glu559 is involved, reversible, 2-step complex formation, competitive with respect to 3-hydroxy-3-methylglutaryl-CoA, non-competitive to NADPH
simvastatin
-
does not allow differentiation between the wild-type and mutant forms of the human protein
additional information
-
27-hydroxycholesterol strongly supresses the expression of HMGR, the in vivo inhibition of sterol 27-hydroxylase CYP27A1, e.g. by the drugs rapamycin and cyclosporine A, reduces the inhibition and thus increases HMGR activity, overview
-
additional information
screening of eight-membered medium ring lactams and related tricyclic compounds, either seven-membered lactams, thiolactams or amines, for inhibitory potency, overview. The compounds are inhibitory also in the presence of increasing concentrations of NADPH, and are not affected by increasing concentrations of HMG-CoA. Medium ring lactams and existing statins may have different mechanisms of enzyme interaction and inhibition, molecular docking studies and comparisons using the HMG-CoA reductase statin-binding receptor model, overview. The ligands may occupy a narrow channel housing the pyridinium moiety on NADP+
-
additional information
-
screening of eight-membered medium ring lactams and related tricyclic compounds, either seven-membered lactams, thiolactams or amines, for inhibitory potency, overview. The compounds are inhibitory also in the presence of increasing concentrations of NADPH, and are not affected by increasing concentrations of HMG-CoA. Medium ring lactams and existing statins may have different mechanisms of enzyme interaction and inhibition, molecular docking studies and comparisons using the HMG-CoA reductase statin-binding receptor model, overview. The ligands may occupy a narrow channel housing the pyridinium moiety on NADP+
-
additional information
-
methanolic extracts of Quercus infectoria galls, Rosa damascena flowers, and Myrtus communis leaves inhibit the enzyme activity noncompetitively to 84%, 70%, and 62%, respectively. Extracts of diverse other plants are also inhibitory for the enzyme, detailed overview
-
additional information
statins are potent enzyme inhibitors that bind to the active site where also the natural substrate binds, used widely in the treatment of hypercholesterolemia
-
additional information
-
design of highly potent and competitive inhibitory peptides for 3-hydroxy-3-methylglutaryl CoA reductase, no inhibition with SFGYVAG peptide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
myristic acid
-
stimulates translation of the enzyme about 1.8fold at 0.15 mM, upregulation
additional information
-
phosphorylation of HMGCR is stimulated by SMase C or exogenous ceramide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death.
Acquired Immunodeficiency Syndrome
Endogenous sodium potassium ATPase inhibition related biochemical cascade and the acquired immunodeficiency syndrome--neural regulation of viral replication and immune response to the virus.
Acquired Immunodeficiency Syndrome
Hypothalamic digoxin, hemispheric dominance and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
Acute Coronary Syndrome
Early statin initiation and outcomes in patients with acute coronary syndromes.
Acute Coronary Syndrome
Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction.
Acute Coronary Syndrome
Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction.
Acute Coronary Syndrome
HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats.
Acute Coronary Syndrome
How aggressive should lipid lowering be among patients with acute coronary syndromes?
Acute Coronary Syndrome
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Acute Coronary Syndrome
Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
Acute Coronary Syndrome
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Acute Coronary Syndrome
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Acute Coronary Syndrome
T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?
Acute Coronary Syndrome
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Acute Coronary Syndrome
[Oxidized low-density lipoprotein enhances the expressions of SREBP-2 and HMGCR mRNA in macrophages derived from the monocytes of patients with acute coronary syndrome]
Acute Kidney Injury
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Acute Kidney Injury
HMG-CoA Reductase Activation and Urinary Pellet Cholesterol Elevations in Acute Kidney Injury.
Acute Kidney Injury
HMG-CoA reductase inhibitors (statins) and acute kidney injury: A secondary analysis of renal study outcomes.
Acute Kidney Injury
Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine.
Acute Kidney Injury
Renal ischemia-induced cholesterol loading: transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene.
Acute Kidney Injury
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Acute Kidney Injury
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.
Acute Kidney Injury
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Acute Lung Injury
Long-term Simvastatin Administration Attenuates Lung Injury and Oxidative Stress in Murine Acute Lung Injury Models Induced by Oleic Acid and Endotoxin.
Acute Lung Injury
Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury.
Adenocarcinoma
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Adenocarcinoma
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Adenocarcinoma
Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.
Adenocarcinoma
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Adenocarcinoma
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Adenocarcinoma of Lung
Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.
Adenocarcinoma of Lung
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
Adenocarcinoma of Lung
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Adenocarcinoma of Lung
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Adenocarcinoma, Bronchiolo-Alveolar
Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
Adenoma
Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism.
Albuminuria
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Albuminuria
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
Albuminuria
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Albuminuria
Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier Injury.
aldehyde dehydrogenase (nad+) deficiency
Acetaldehyde Dehydrogenase 2 regulates HMG-CoA reductase stability and cholesterol synthesis in the liver.
Alveolitis, Extrinsic Allergic
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
Alzheimer Disease
A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations.
Alzheimer Disease
Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.
Alzheimer Disease
Atorvastatin ameliorates cognitive impairment, A?1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.
Alzheimer Disease
Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression.
Alzheimer Disease
Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
Alzheimer Disease
Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.
Alzheimer Disease
Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
Alzheimer Disease
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Alzheimer Disease
Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.
Alzheimer Disease
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
Alzheimer Disease
Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk.
Alzheimer Disease
High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.
Alzheimer Disease
HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
Alzheimer Disease
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
Alzheimer Disease
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.
Alzheimer Disease
Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk.
Alzheimer Disease
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Alzheimer Disease
Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins.
Alzheimer Disease
Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease.
Alzheimer Disease
Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.
Alzheimer Disease
Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimer's Disease.
Alzheimer Disease
Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.
Amebiasis
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
Amyotrophic Lateral Sclerosis
Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.
Anaphylaxis
Exercise-Induced Anaphylaxis in an Air Force Aviator Taking a HMG-CoA Reductase Inhibitor: A Case Report and Review of the Presentation, Diagnoses, and Treatment.
Anemia, Hypochromic
Overexpression of farnesyl diphosphate synthase in Arabidopsis mitochondria triggers light-dependent lesion formation and alters cytokinin homeostasis.
Aneurysm
A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
Angina Pectoris
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Angina, Stable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Angina, Stable
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Angina, Unstable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Angina, Unstable
Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
Angina, Unstable
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
Angina, Unstable
[Statins decreases expression of five inflammation-associated microRNAs in the plasma of patients with unstable angina].
Aortic Aneurysm, Abdominal
A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
Aortic Aneurysm, Abdominal
A Randomised Placebo-controlled Double-blind Trial to Evaluate Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in Abdominal Aortic Aneurysms.
Aortic Aneurysm, Abdominal
HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms.
Aortic Valve Stenosis
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Aortic Valve Stenosis
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Arterial Occlusive Diseases
Peripheral arterial disease: a review of disease awareness and management.
Arteriosclerosis
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Arteriosclerosis
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Arteriosclerosis
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Arteriosclerosis
Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study.
Arteritis
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women.
Arthritis
Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis.
Arthritis
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Arthritis, Rheumatoid
Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients.
Arthritis, Rheumatoid
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Arthritis, Rheumatoid
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.
Aspergillosis, Allergic Bronchopulmonary
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Asthma
Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice.
Asthma
Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model.
Asthma
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Asthma
Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Asthma
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Asthma
Statin Exposure is Associated with Decreased Asthma-Related Emergency Department Visits and Oral Corticosteroid Use.
Asthma
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Asthma
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Atherosclerosis
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
Atherosclerosis
A Comprehensive Review of Oxidative Stress as the Underlying Mechanism in Atherosclerosis and the Inefficiency of Antioxidants to Revert this Process.
Atherosclerosis
A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.
Atherosclerosis
A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
Atherosclerosis
A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits.
Atherosclerosis
A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
Atherosclerosis
Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells.
Atherosclerosis
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Atherosclerosis
Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice.
Atherosclerosis
An in vitro method using vascular smooth muscle cells to study the effect of compounds on cell proliferation and intracellular lipid accumulation.
Atherosclerosis
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Atherosclerosis
Antihypercholesterolemic and antiatherosclerotic potencies of Pandanus tectorius fruits via increasing scavenger receptor-B1 genes expression and inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Atherosclerosis
Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.
Atherosclerosis
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Atherosclerosis
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Atherosclerosis
Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins.
Atherosclerosis
Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis.
Atherosclerosis
Biological knowledge-driven analysis of epistasis in human GWAS with application to lipid traits.
Atherosclerosis
Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice.
Atherosclerosis
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Atherosclerosis
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Atherosclerosis
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Atherosclerosis
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Atherosclerosis
Coronary Plaque Burden at Coronary CT Angiography in Asymptomatic Men and Women.
Atherosclerosis
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Atherosclerosis
Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
Atherosclerosis
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Atherosclerosis
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Atherosclerosis
Diabetes mellitus-associated atherosclerosis : mechanisms involved and potential for pharmacological invention.
Atherosclerosis
Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system.
Atherosclerosis
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Atherosclerosis
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Atherosclerosis
Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.
Atherosclerosis
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Atherosclerosis
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Atherosclerosis
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.
Atherosclerosis
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
Atherosclerosis
Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
Atherosclerosis
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Atherosclerosis
Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
Atherosclerosis
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Atherosclerosis
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Atherosclerosis
Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals.
Atherosclerosis
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Atherosclerosis
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Atherosclerosis
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
Atherosclerosis
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Atherosclerosis
HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis.
Atherosclerosis
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Atherosclerosis
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Atherosclerosis
HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol.
Atherosclerosis
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Atherosclerosis
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
Atherosclerosis
Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.
Atherosclerosis
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Atherosclerosis
Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells.
Atherosclerosis
In vitro screening for ?-hydroxy-?-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
Atherosclerosis
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Atherosclerosis
Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy.
Atherosclerosis
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Atherosclerosis
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Atherosclerosis
Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy?
Atherosclerosis
Knowledge-driven analysis identifies a gene-gene interaction affecting high-density lipoprotein cholesterol levels in multi-ethnic populations.
Atherosclerosis
L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix.
Atherosclerosis
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Atherosclerosis
Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Atherosclerosis
Lycopene regulation of cholesterol synthesis and efflux in human macrophages.
Atherosclerosis
Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
Atherosclerosis
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Atherosclerosis
Molecular mechanisms underlying the onset of degenerative aortic valve disease.
Atherosclerosis
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Atherosclerosis
Myeloid HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) Reductase Determines Atherosclerosis by Modulating Migration of Macrophages.
Atherosclerosis
Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
Atherosclerosis
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Atherosclerosis
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Atherosclerosis
Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.
Atherosclerosis
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Atherosclerosis
Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine.
Atherosclerosis
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Atherosclerosis
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Atherosclerosis
Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study.
Atherosclerosis
Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors.
Atherosclerosis
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Atherosclerosis
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Atherosclerosis
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Atherosclerosis
Rosuvastatin Improves Endothelial Function of db/db Mice: Role of Angiotensin II Type 1 Receptors and Oxidative Stress.
Atherosclerosis
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Atherosclerosis
Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1-PPAR?-CD36 pathway.
Atherosclerosis
Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA.
Atherosclerosis
Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
Atherosclerosis
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Atherosclerosis
Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.
Atherosclerosis
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Atherosclerosis
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.
Atherosclerosis
Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS).
Atherosclerosis
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
Atherosclerosis
The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.
Atherosclerosis
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Atherosclerosis
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
Atherosclerosis
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
Atherosclerosis
The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
Atherosclerosis
The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.
Atherosclerosis
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Atherosclerosis
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Atherosclerosis
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Atherosclerosis
Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin.
Atherosclerosis
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Atherosclerosis
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]
Atherosclerosis
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
Atrial Fibrillation
Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin?
Atrial Fibrillation
Fluvastatin Reduces Pulmonary Vein Spontaneous Activity Through Nitric Oxide Pathway.
Atrial Fibrillation
Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
Atrial Fibrillation
Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies.
Atrial Fibrillation
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery.
Atrial Fibrillation
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Atrial Fibrillation
Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during post-myocardial infarction remodeling process.
Atrial Fibrillation
Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Atrial Fibrillation
Targeting inflammation and oxidative stress in atrial fibrillation: Role of HMG-CoA reductase inhibition with statins.
Atrial Fibrillation
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
Autoimmune Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Autoimmune Diseases
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
Autoimmune Diseases
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Autoimmune Diseases
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
Autoimmune Diseases
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Autoimmune Diseases
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Bacterial Infections
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Bacterial Infections
Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
Blepharitis
HMG-CoA reductase expression in human eyelid tissue and in a human meibomian gland epithelial cell line.
Blister
3-hydroxy-3-methyl glutaryl coenzyme A reductase: an essential actor in the biosynthesis of cantharidin in the blister beetle Epicauta chinensis Laporte.
Bone Resorption
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
Bone Resorption
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Brain Injuries
HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons.
Brain Injuries
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Brain Injuries
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: A translational approach.
Brain Injuries
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Brain Injuries, Traumatic
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Brain Injuries, Traumatic
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
Brain Injuries, Traumatic
Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
Brain Injuries, Traumatic
Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
Brain Injuries, Traumatic
Statins and neuroprotection: a prescription to move the field forward.
Brain Ischemia
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Brain Ischemia
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Brain Ischemia
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Brain Ischemia
Alterations of interneurons of the gerbil hippocampus after transient cerebral ischemia: effect of pitavastatin.
Brain Ischemia
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
Brain Ischemia
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Brain Ischemia
HMG-CoA Reductase Inhibitors Relieve Endoplasmic Reticulum Stress by Autophagy Inhibition in Rats With Permanent Brain Ischemia.
Brain Ischemia
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Brain Ischemia
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Brain Ischemia
[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]
Breast Neoplasms
17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
Breast Neoplasms
A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer.
Breast Neoplasms
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
Breast Neoplasms
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Breast Neoplasms
Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism.
Breast Neoplasms
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Breast Neoplasms
Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk.
Breast Neoplasms
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
Breast Neoplasms
Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.
Breast Neoplasms
CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-? signaling.
Breast Neoplasms
Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development.
Breast Neoplasms
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Breast Neoplasms
Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway.
Breast Neoplasms
Factors released from human breast-cancer cells counteract the inhibitory effects of mevinolin on DNA-synthesis and morphology but not on hmg coa reductase-activity.
Breast Neoplasms
Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Breast Neoplasms
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Breast Neoplasms
HMG CoA reductase expression as a prognostic factor in Korean patients with breast cancer: A retrospective study.
Breast Neoplasms
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Breast Neoplasms
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Breast Neoplasms
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Breast Neoplasms
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Breast Neoplasms
Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.
Breast Neoplasms
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
Breast Neoplasms
MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Breast Neoplasms
Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.
Breast Neoplasms
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.
Breast Neoplasms
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Breast Neoplasms
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
Breast Neoplasms
Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells.
Breast Neoplasms
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Breast Neoplasms
Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Breast Neoplasms
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Breast Neoplasms
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Breast Neoplasms
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
Breast Neoplasms
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug.
Breast Neoplasms
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Breast Neoplasms
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Breast Neoplasms
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Breast Neoplasms, Male
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
Bronchitis, Chronic
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Carcinogenesis
A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis.
Carcinogenesis
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice.
Carcinogenesis
Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.
Carcinogenesis
Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice.
Carcinogenesis
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
Carcinogenesis
Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.
Carcinogenesis
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Carcinogenesis
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Carcinogenesis
Hypolipidemic effect of ginger in 1,2-dimethyl hydrazine-induced experimental colon carcinogenesis.
Carcinogenesis
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Carcinogenesis
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Carcinogenesis
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Carcinogenesis
Regulation of mevalonate synthesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids.
Carcinogenesis
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Carcinogenesis
Taxifolin binds with LXR (? & ?) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway.
Carcinogenesis
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases.
Carcinoma
3-Hydroxy-3-methylglutaryl coenzyme a reductase activity in liver of athymic mice with or without an implanted human carcinoma.
Carcinoma
A New Survival Model Based on Cholesterol Biosynthesis-Related Genes for Prognostic Prediction in Clear Cell Renal Cell Carcinoma.
Carcinoma
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Carcinoma
Characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human adrenal cortex.
Carcinoma
Chemical Pathology of Homocysteine VIII. Effects of Tocotrienol, Geranylgeraniol, and Squalene on Thioretinaco Ozonide, Mitochondrial Permeability, and Oxidative Phosphorylation in Arteriosclerosis, Cancer, Neurodegeneration and Aging.
Carcinoma
Diosgenin, a naturally occurring furostanol saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells.
Carcinoma
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Carcinoma
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
Carcinoma
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
Carcinoma
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
Carcinoma
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Carcinoma
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
Carcinoma
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Carcinoma
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Carcinoma
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
Carcinoma
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Carcinoma
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Carcinoma
SREBP2 is upregulated in esophageal squamous cell carcinoma and co?operates with c?Myc to regulate HMGCR expression.
Carcinoma
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Carcinoma
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Carcinoma
Synergistic Impact of d-?-Tocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells.
Carcinoma, Acinar Cell
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Carcinoma, Hepatocellular
A sensitive RNase protection assay for the quantitation of the mRNAs for the LDL receptor and HMG-CoA reductase in human total RNA. Effects of treatments on cells in culture designed to up- and down-regulate expression of the LDL receptor.
Carcinoma, Hepatocellular
Activation of AMP-kinase by Policosanol Requires Peroxisomal Metabolism.
Carcinoma, Hepatocellular
Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors.
Carcinoma, Hepatocellular
An improved assay of 3-hydroxy-3-methylglutaryl-CoA reductase activity in Reuber H35 hepatoma cells without microsomes isolation.
Carcinoma, Hepatocellular
Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase.
Carcinoma, Hepatocellular
Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
Carcinoma, Hepatocellular
Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin.
Carcinoma, Hepatocellular
Cholesterol-lowering effect of Aralia elata (Miq.) Seem via the activation of SREBP-2 and the LDL receptor.
Carcinoma, Hepatocellular
Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Carcinoma, Hepatocellular
Comparison of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma cells grown in vivo and in vitro.
Carcinoma, Hepatocellular
Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels.
Carcinoma, Hepatocellular
Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a human hepatoma cell line, HepG2.
Carcinoma, Hepatocellular
Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells.
Carcinoma, Hepatocellular
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Carcinoma, Hepatocellular
Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells.
Carcinoma, Hepatocellular
Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway.
Carcinoma, Hepatocellular
Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
Carcinoma, Hepatocellular
Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells.
Carcinoma, Hepatocellular
Growth-rate-related and hydroxysterol-induced changes in membrane fluidity of cultured hepatoma cells: correlation with 3-hydroxy-3-methyl glutaryl CoA reductase activity.
Carcinoma, Hepatocellular
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.
Carcinoma, Hepatocellular
HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis.
Carcinoma, Hepatocellular
Identification of insulin-responsive regions in the HMG-CoA reductase promoter.
Carcinoma, Hepatocellular
Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis.
Carcinoma, Hepatocellular
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in hepatoma tissue culture cells by pure cholesterol and several cholesterol derivatives. Evidence supporting two distinct mechanisms.20l.
Carcinoma, Hepatocellular
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Carcinoma, Hepatocellular
Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels.
Carcinoma, Hepatocellular
Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.
Carcinoma, Hepatocellular
Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
Carcinoma, Hepatocellular
MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1.
Carcinoma, Hepatocellular
Modification of phospholipids fatty acid composition in reuber H35 hepatoma cells: effect on HMG-CoA reductase activity.
Carcinoma, Hepatocellular
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase.
Carcinoma, Hepatocellular
NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells.
Carcinoma, Hepatocellular
Partial "feedback control" of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in primary hepatocellular carcinomas.
Carcinoma, Hepatocellular
Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice.
Carcinoma, Hepatocellular
Plasma membrane sphingomyelin and the regulation of HMG-CoA reductase activity and cholesterol biosynthesis in cell cultures.
Carcinoma, Hepatocellular
Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
Carcinoma, Hepatocellular
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Carcinoma, Hepatocellular
Properties of 3-hydroxy-3-methylglutaryl coenzyme A reductase solubilized from rat liver and hepatoma.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma tissue culture cells by serum lipoproteins.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase in minimal deviation hepatoma 7288C. Immunological measurements in hepatoma tissue culture cells.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatomas 5123C, 9618A and 5123t.c.
Carcinoma, Hepatocellular
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Carcinoma, Hepatocellular
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Carcinoma, Hepatocellular
Regulation of the Lactobacillus Strains on HMGCoA Reductase Gene Transcription in Human HepG2 Cells via Nuclear Factor-?B.
Carcinoma, Hepatocellular
Regulation of the rate of sterol synthesis and the level of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in mouse liver and hepatomas.
Carcinoma, Hepatocellular
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Carcinoma, Hepatocellular
Reversible phosphorylation of 3-hydroxy-3-methylglutaryl CoA reductase in Morris hepatomas.
Carcinoma, Hepatocellular
RHOA is a modulator of the cholesterol-lowering effects of statin.
Carcinoma, Hepatocellular
Robinetinidol-flavone attenuates cholesterol synthesis in hepatoma cells via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Carcinoma, Hepatocellular
Role of mevalonate in regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured cells and their cytoplasts.
Carcinoma, Hepatocellular
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Carcinoma, Hepatocellular
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Carcinoma, Hepatocellular
Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: A PXR dependent mechanism.
Carcinoma, Hepatocellular
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.
Carcinoma, Hepatocellular
Supernatant protein factor requires phosphorylation and interaction with Golgi to stimulate cholesterol synthesis in hepatoma cells.
Carcinoma, Hepatocellular
Suppression of rat liver tumorigenesis by 25-hydroxycholesterol and all-trans retinoic acid: differentiation therapy for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
Carcinoma, Hepatocellular
Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2.
Carcinoma, Hepatocellular
The effect of 25-hydroxycholesterol on the regulation of apolipoprotein E mRNA levels and secretion in the human hepatoma HepG2.
Carcinoma, Hepatocellular
The regulation of beta-hydroxy-beta-methylglutaryl coenzyme A reductase in Morris hepatomas 5123C, 7800, and 9618A.
Carcinoma, Hepatocellular
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
Carcinoma, Hepatocellular
[Affinity of 3-beta-(2-hydroxyethoxy)-5-alpha-cholest-8(14)-ene-15-one to oxysterol binding protein and its metabolism in HepG2 hepatoma cells]
Carcinoma, Hepatocellular
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
Carcinoma, Intraductal, Noninfiltrating
The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Carcinoma, Mucoepidermoid
Simvastatin effects on a human lung carcinoma and cholesterol homeostasis of host and non-host mice.
Carcinoma, Ovarian Epithelial
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Impact of statin therapy on survival in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Carcinoma, Renal Cell
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Carcinoma, Renal Cell
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
Carcinoma, Renal Cell
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Carcinoma, Renal Cell
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Carcinoma, Renal Cell
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Cardiomegaly
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Cardiomegaly
HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Cardiomegaly
Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy.
Cardiomegaly
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Cardiomegaly
Matrix Metalloproteinase-2 Mediates a Mechanism of Metabolic Cardioprotection Consisting of Negative Regulation of the Sterol Regulatory Element-Binding Protein-2/3-Hydroxy-3-Methylglutaryl-CoA Reductase Pathway in the Heart.
Cardiomegaly
Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy.
Cardiomegaly
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Cardiomegaly
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
Cardiomegaly
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.
Cardiomegaly
Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway.
Cardiomegaly
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Cardiomyopathies
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Cardiomyopathy, Hypertrophic
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Cardiotoxicity
Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors.
Cardiovascular Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
Cardiovascular Diseases
?-Cell-Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of ?-Cell Mass and Impaired Insulin Secretion.
Cardiovascular Diseases
A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.
Cardiovascular Diseases
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Cardiovascular Diseases
A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
Cardiovascular Diseases
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.
Cardiovascular Diseases
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Cardiovascular Diseases
An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.
Cardiovascular Diseases
An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat.
Cardiovascular Diseases
Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-?B and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264.7 macrophages.
Cardiovascular Diseases
Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules.
Cardiovascular Diseases
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions.
Cardiovascular Diseases
Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?: A Retrospective Cohort Study.
Cardiovascular Diseases
Association Between Statin Use and Prevalence of Exercise-Related Injuries: A Cross-Sectional Survey of Amateur Runners in the Netherlands.
Cardiovascular Diseases
Association of race with cumulative exposure to statins in dialysis.
Cardiovascular Diseases
Atorvastatin disrupts primary human brain microvascular endothelial cell functions via prenylation-dependent mitochondrial inhibition and oxidative stress.
Cardiovascular Diseases
Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation.
Cardiovascular Diseases
Atorvastatin inhibited TNF-? induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-?B signaling.
Cardiovascular Diseases
Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression.
Cardiovascular Diseases
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Cardiovascular Diseases
Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Cardiovascular Diseases
Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Cardiovascular Diseases
Clinical implications of pharmacogenetic variation on the effects of statins.
Cardiovascular Diseases
Clinically relevant drug interactions between statins and antidepressants.
Cardiovascular Diseases
Combination Therapy of Amlodipine and Atorvastatin Has More Beneficial Vascular Effects Than Monotherapy in Salt-Sensitive Hypertension.
Cardiovascular Diseases
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Cardiovascular Diseases
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Cardiovascular Diseases
Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).
Cardiovascular Diseases
Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Cardiovascular Diseases
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Cardiovascular Diseases
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Cardiovascular Diseases
Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice.
Cardiovascular Diseases
Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol.
Cardiovascular Diseases
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Cardiovascular Diseases
Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
Cardiovascular Diseases
Effect of statins on breast cancer recurrence and mortality: a review.
Cardiovascular Diseases
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Cardiovascular Diseases
Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Cardiovascular Diseases
Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Cardiovascular Diseases
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Cardiovascular Diseases
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Cardiovascular Diseases
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Cardiovascular Diseases
Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats.
Cardiovascular Diseases
Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism.
Cardiovascular Diseases
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Cardiovascular Diseases
Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
Cardiovascular Diseases
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Cardiovascular Diseases
Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Cardiovascular Diseases
Identification of novel inhibitors of dietary lipid absorption using zebrafish.
Cardiovascular Diseases
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Cardiovascular Diseases
Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
Cardiovascular Diseases
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Cardiovascular Diseases
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Cardiovascular Diseases
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Cardiovascular Diseases
Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges.
Cardiovascular Diseases
Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal.
Cardiovascular Diseases
Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective.
Cardiovascular Diseases
Molecular mechanisms underlying the effects of statins in the central nervous system.
Cardiovascular Diseases
Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.
Cardiovascular Diseases
Neuroprotective Effect of Simvastatin via Inducing the Autophagy on Spinal Cord Injury in the Rat Model.
Cardiovascular Diseases
On- and Off-Target Pharmacology of Torcetrapib: Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors.
Cardiovascular Diseases
Optimal therapy of low levels of high density lipoprotein-cholesterol.
Cardiovascular Diseases
Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
Cardiovascular Diseases
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Cardiovascular Diseases
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Cardiovascular Diseases
Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells.
Cardiovascular Diseases
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
Cardiovascular Diseases
Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin.
Cardiovascular Diseases
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Cardiovascular Diseases
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Cardiovascular Diseases
Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
Cardiovascular Diseases
Potential role of statin therapy in heart failure, atrial fibrillation and aortic stenosis.
Cardiovascular Diseases
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Cardiovascular Diseases
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Cardiovascular Diseases
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Cardiovascular Diseases
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Cardiovascular Diseases
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Cardiovascular Diseases
Role of bile acid sequestrants in the treatment of type 2 diabetes.
Cardiovascular Diseases
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date.
Cardiovascular Diseases
Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field.
Cardiovascular Diseases
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Cardiovascular Diseases
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Cardiovascular Diseases
Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice.
Cardiovascular Diseases
Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na+ and Ca2+ influx in bovine adrenal medullary cells.
Cardiovascular Diseases
Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes.
Cardiovascular Diseases
Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1.
Cardiovascular Diseases
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Cardiovascular Diseases
Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling.
Cardiovascular Diseases
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Cardiovascular Diseases
Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?
Cardiovascular Diseases
Statin use and breast cancer: do we need more evidence and what should this be?
Cardiovascular Diseases
Statin-Associated Necrotizing Myopathy Leading to Acute Kidney Injury: A Case Report.
Cardiovascular Diseases
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Cardiovascular Diseases
Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms and Clinical Implications.
Cardiovascular Diseases
Statins and venous thromboembolism: do they represent a viable therapeutic agent?
Cardiovascular Diseases
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.
Cardiovascular Diseases
Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
Cardiovascular Diseases
Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms.
Cardiovascular Diseases
Statins in acute coronary syndrome: very early initiation and benefits.
Cardiovascular Diseases
Statins potently reduce the cytokine-mediated IL-6 release in SMC / MNC cocultures.
Cardiovascular Diseases
Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation.
Cardiovascular Diseases
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Cardiovascular Diseases
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Cardiovascular Diseases
The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review.
Cardiovascular Diseases
The effects of lipid-lowering agents on acute renal allograft rejection.
Cardiovascular Diseases
The effects of statins on endothelium, inflammation and cardioprotection.
Cardiovascular Diseases
The Impact of Exercise on Statin-Associated Skeletal Muscle Myopathy.
Cardiovascular Diseases
The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.
Cardiovascular Diseases
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
Cardiovascular Diseases
The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy.
Cardiovascular Diseases
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Cardiovascular Diseases
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Cardiovascular Diseases
Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Cardiovascular Diseases
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Cardiovascular Diseases
[18F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats.
Cardiovascular Diseases
[HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials]
Cardiovascular Diseases
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
Cardiovascular Diseases
[Inhibitors of HMG CoA reductase: new modes of action, new indications?]
Cardiovascular Diseases
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
Cardiovascular Diseases
[Regulatory Mechanisms and Practical Management in Vascular Calcification. Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment.]
Carotid Artery Diseases
Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors.
Carotid Artery Diseases
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Carotid Artery Diseases
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
Carotid Stenosis
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Carotid Stenosis
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Cataract
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Cataract
Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats.
Cataract
On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
Cataract
The Polymorphism rs2968 of LSS Gene Confers Susceptibility to Age-Related Cataract.
Cataract
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Central Nervous System Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
Central Nervous System Diseases
Functional Expression of Organic Anion Transporting Polypeptide 1a4 (Oatp1a4) is Regulated by Transforming Growth Factor-/Activin Receptor-like Kinase 1 (TGF-/ALK1) Signaling at the Blood-Brain Barrier.
Central Nervous System Neoplasms
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Cerebral Hemorrhage
HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Cerebral Hemorrhage
Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis.
Cerebral Hemorrhage
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.
Cerebral Infarction
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Cerebral Infarction
Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
Cerebral Infarction
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Cerebral Infarction
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Cerebrovascular Disorders
Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.
Cerebrovascular Disorders
Direct free radical scavenging effects of water-soluble HMG-CoA reductase inhibitors.
Cerebrovascular Disorders
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Cerebrovascular Disorders
Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Cerebrovascular Disorders
Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice.
Cerebrovascular Disorders
Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats.
Cerebrovascular Disorders
Simvastatin treatment in surgically induced brain injury in rats.
Cerebrovascular Disorders
Statins and neuroprotection: a prescription to move the field forward.
Cerebrovascular Disorders
Statins therapy: a review on conventional and novel formulation approaches.
Chemical and Drug Induced Liver Injury
Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury.
Cholangiocarcinoma
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Cholelithiasis
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Cholelithiasis
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Cholelithiasis
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Cholelithiasis
Hepatic microsomal activities of cholesterol 7 alpha-hydroxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in the prairie dog. An animal model for cholesterol gallstone disease.
Cholelithiasis
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Cholelithiasis
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Cholelithiasis
Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Cholestasis
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Cholestasis
Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats.
Cholesterol Ester Storage Disease
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Cholesterol Ester Storage Disease
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Cholesterol Ester Storage Disease
Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease.
Choriocarcinoma
Regulation by plasma lipoproteins of progesterone biosynthesis and 3-hydroxy-3-methyl glutaryl coenzyme a reductase activity in cultured human choriocarcinoma cells.
Choroidal Neovascularization
Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice.
Colitis
Geranylgeranyl pyrophosphate amplifies Treg differentiation via increased IL-2 expression to ameliorate DSS-induced colitis.
Colitis
Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
Colitis
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.
Colitis, Ulcerative
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Colonic Neoplasms
Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line.
Colonic Neoplasms
Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell line.
Colonic Neoplasms
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Colonic Neoplasms
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Colonic Neoplasms
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Colonic Neoplasms
HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Colonic Neoplasms
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Colonic Neoplasms
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Colonic Neoplasms
Statins in the chemoprevention of colorectal cancer in established animal models of sporadic and colitis-associated cancer.
Colonic Neoplasms
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Colonic Neoplasms
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer.
Colorectal Neoplasms
Current data with HMG-CoA reductase inhibitors (statins) for colorectal cancer prevention.
Colorectal Neoplasms
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Colorectal Neoplasms
Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor.
Colorectal Neoplasms
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Colorectal Neoplasms
Expression of miR-18a-5p, miR-144-3p, and miR-663b in colorectal cancer and their association with cholesterol homeostasis.
Colorectal Neoplasms
Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas.
Colorectal Neoplasms
Gamma-tocopherol enhances apoptotic effects of lovastatin in human colorectal carcinoma cell line (HT29).
Colorectal Neoplasms
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Colorectal Neoplasms
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Colorectal Neoplasms
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Colorectal Neoplasms
Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice.
Colorectal Neoplasms
Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis.
Colorectal Neoplasms
Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study.
Colorectal Neoplasms
Statin use and the risk of colorectal cancer in a population-based electronic health records study.
Colorectal Neoplasms
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Colorectal Neoplasms
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Colorectal Neoplasms
Targeting triglyceride metabolism for colorectal cancer prevention and therapy.
Colorectal Neoplasms
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
Communicable Diseases
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Confusion
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
Connective Tissue Diseases
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.
Connective Tissue Diseases
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective.
Corneal Dystrophies, Hereditary
Schnyder Corneal Dystrophy-Associated UBIAD1 is Defective in MK-4 Synthesis and Resists Autophagy-Mediated Degradation.
Coronary Artery Disease
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
Coronary Artery Disease
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Coronary Artery Disease
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Coronary Artery Disease
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Coronary Artery Disease
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Coronary Artery Disease
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Coronary Artery Disease
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
Coronary Artery Disease
Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese.
Coronary Artery Disease
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Coronary Artery Disease
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Coronary Artery Disease
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Coronary Artery Disease
Do statins prevent heart failure in patients after myocardial infarction?
Coronary Artery Disease
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
Coronary Artery Disease
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Coronary Artery Disease
Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: A Post Hoc Analysis of Data from a Prospective, Randomized, Double-Blind Study.
Coronary Artery Disease
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Coronary Artery Disease
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Coronary Artery Disease
Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
Coronary Artery Disease
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
Coronary Artery Disease
Effect of statins on atherogenic serum amyloid A and ?1-antitrypsin low-density lipoprotein complexes.
Coronary Artery Disease
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Coronary Artery Disease
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Coronary Artery Disease
Effects of lovastatin and pravastatin on cognitive function in military aircrew.
Coronary Artery Disease
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Coronary Artery Disease
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Coronary Artery Disease
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Coronary Artery Disease
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Coronary Artery Disease
Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Coronary Artery Disease
Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation.
Coronary Artery Disease
Evaluation of the promoter polymorphism -911C>A in the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase gene with coronary artery disease risk and cholesterol levels in a population from Western India.
Coronary Artery Disease
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
Coronary Artery Disease
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
Coronary Artery Disease
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Coronary Artery Disease
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
Coronary Artery Disease
HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.
Coronary Artery Disease
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
Coronary Artery Disease
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Coronary Artery Disease
HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms?
Coronary Artery Disease
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Coronary Artery Disease
IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
Coronary Artery Disease
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Coronary Artery Disease
Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy.
Coronary Artery Disease
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
Coronary Artery Disease
Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Coronary Artery Disease
Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic.
Coronary Artery Disease
Medical management of coronary artery disease revisited: the endothelial factor.
Coronary Artery Disease
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Coronary Artery Disease
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Coronary Artery Disease
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Coronary Artery Disease
Pathophysiology and treatment of lipid perturbation after cardiac transplantation.
Coronary Artery Disease
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Coronary Artery Disease
Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.
Coronary Artery Disease
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Coronary Artery Disease
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
Coronary Artery Disease
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Coronary Artery Disease
Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis.
Coronary Artery Disease
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Coronary Artery Disease
Provider adherence to clinical guidelines related to lipid-lowering medications.
Coronary Artery Disease
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Coronary Artery Disease
Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention.
Coronary Artery Disease
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Coronary Artery Disease
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Coronary Artery Disease
Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
Coronary Artery Disease
Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
Coronary Artery Disease
Role of circulating lipid abnormalities in chronic renal allograft rejection.
Coronary Artery Disease
Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients.
Coronary Artery Disease
Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart.
Coronary Artery Disease
The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
Coronary Artery Disease
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
Coronary Artery Disease
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
Coronary Artery Disease
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
Coronary Artery Disease
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
Coronary Artery Disease
The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
Coronary Artery Disease
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Coronary Artery Disease
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Coronary Artery Disease
Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
Coronary Artery Disease
[Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits]
Coronary Artery Disease
[The impact HMG-CoA reductase inhibitors in the modification of the natural history of coronary artery disease]
Coronary Artery Disease
[The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease]
Coronary Disease
8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease.
Coronary Disease
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
Coronary Disease
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Coronary Disease
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Coronary Disease
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Coronary Disease
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine.
Coronary Disease
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Coronary Disease
Combined QSAR model and chemical similarity search for novel HMG-CoA reductase inhibitors for coronary heart disease.
Coronary Disease
Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
Coronary Disease
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Coronary Disease
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Coronary Disease
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Coronary Disease
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Coronary Disease
Debate: at what level of coronary heart disease risk should a statin be prescribed?
Coronary Disease
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Coronary Disease
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Coronary Disease
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Coronary Disease
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Coronary Disease
Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Coronary Disease
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Coronary Disease
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Coronary Disease
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Coronary Disease
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Coronary Disease
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
Coronary Disease
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Coronary Disease
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Coronary Disease
HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease.
Coronary Disease
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Coronary Disease
Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
Coronary Disease
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Coronary Disease
Niacin or ezetimibe for patients with, or at risk of coronary heart disease.
Coronary Disease
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Coronary Disease
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Coronary Disease
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Coronary Disease
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
Coronary Disease
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Coronary Disease
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Coronary Disease
Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
Coronary Disease
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Coronary Disease
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies.
Coronary Disease
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Coronary Disease
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Coronary Disease
Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
Coronary Disease
Results of recent large cholesterol-lowering trials and implications for clinical management.
Coronary Disease
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Coronary Disease
Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
Coronary Disease
Statin therapy in the elderly: does it make good clinical and economic sense?
Coronary Disease
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Coronary Disease
Statins for cardiovascular prevention according to different strategies: a cost analysis.
Coronary Disease
Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Coronary Disease
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Coronary Disease
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Coronary Disease
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
Coronary Disease
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Coronary Disease
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
Coronary Disease
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
Coronary Disease
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Coronary Disease
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
Coronary Disease
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
Coronary Disease
[HMG-CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality]
Coronary Disease
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
Coronary Disease
[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease]
Coronary Disease
[The role of cholesterol-lowering drugs in prevention of coronary heart disease]
Coronary Restenosis
Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis.
Coronary Stenosis
Positron emission tomography and the changing paradigm in coronary artery disease.
Cough
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
COVID-19
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
COVID-19
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
Cystic Fibrosis
Mechanistic similarities between cultured cell models of cystic fibrosis and niemann-pick type C.
Death, Sudden, Cardiac
Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
Deglutition Disorders
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Dehydration
Effect of prolonged water stress on essential oil content, compositions and gene expression patterns of mono- and sesquiterpene synthesis in two oregano (Origanum vulgare L.) subspecies.
Dementia
Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up.
Dementia
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Dementia
Risk factors for dementia with type 2 diabetes mellitus among elderly people in China.
Dementia
The Effect of HMG: CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study.
Dementia
The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
Dementia, Vascular
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Demyelinating Diseases
Tellurium causes dose-dependent coordinate down-regulation of myelin gene expression.
Dengue
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Dermatitis, Phototoxic
Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts.
Dermatitis, Phototoxic
The phototoxicity of fluvastatin, an HMG-CoA reductase inhibitor, is mediated by the formation of a benzocarbazole-like photoproduct.
Dermatomyositis
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Diabetes Mellitus
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Diabetes Mellitus
Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis.
Diabetes Mellitus
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Diabetes Mellitus
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Diabetes Mellitus
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Diabetes Mellitus
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Diabetes Mellitus
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Diabetes Mellitus
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Diabetes Mellitus
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Diabetes Mellitus
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Diabetes Mellitus
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Diabetes Mellitus
Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
Diabetes Mellitus
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Diabetes Mellitus
Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats.
Diabetes Mellitus
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Diabetes Mellitus
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
Diabetes Mellitus
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
Diabetes Mellitus
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Diabetes Mellitus
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Diabetes Mellitus
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Diabetes Mellitus
Recrudescence of Old Stroke Deficits Among Transient Neurological Attacks.
Diabetes Mellitus
Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).
Diabetes Mellitus
REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
Diabetes Mellitus
Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.
Diabetes Mellitus
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Diabetes Mellitus
Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.
Diabetes Mellitus
Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
Diabetes Mellitus
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Diabetes Mellitus
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Diabetes Mellitus
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Diabetes Mellitus
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Diabetes Mellitus
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Diabetes Mellitus
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Diabetes Mellitus, Experimental
Influence of streptozotocin diabetes on intestinal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the rat.
Diabetes Mellitus, Type 1
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Diabetes Mellitus, Type 1
High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
The protective effect of simvastatin against low dose streptozotocin induced type 1 diabetes in mice is independent of inhibition of HMG-CoA reductase.
Diabetes Mellitus, Type 2
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Diabetes Mellitus, Type 2
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Diabetes Mellitus, Type 2
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Diabetes Mellitus, Type 2
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Diabetes Mellitus, Type 2
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Diabetes Mellitus, Type 2
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Diabetes Mellitus, Type 2
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Diabetes Mellitus, Type 2
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Diabetes Mellitus, Type 2
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Diabetes Mellitus, Type 2
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Diabetes Mellitus, Type 2
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Diabetes Mellitus, Type 2
Dose-dependent effect of hydroxymethylglutaryl-coenzyme A reductase inhibitor on serum cholesterol with limited dietary restrictions: a case study.
Diabetes Mellitus, Type 2
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Diabetes Mellitus, Type 2
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
Diabetes Mellitus, Type 2
Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Diabetes Mellitus, Type 2
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Diabetes Mellitus, Type 2
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Diabetes Mellitus, Type 2
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
Diabetes Mellitus, Type 2
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Diabetes Mellitus, Type 2
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Diabetes Mellitus, Type 2
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Diabetes Mellitus, Type 2
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Diabetes Mellitus, Type 2
Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes.
Diabetes Mellitus, Type 2
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Diabetes Mellitus, Type 2
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Diabetes Mellitus, Type 2
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Diabetes Mellitus, Type 2
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Diabetes Mellitus, Type 2
Should the insulin resistance syndrome be treated in the elderly?
Diabetes Mellitus, Type 2
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.
Diabetes Mellitus, Type 2
The antiviral effect of metformin on zika and dengue virus infection.
Diabetes Mellitus, Type 2
The Association of 3-Hydroxy-3-Methylglutaryl-CoA Reductase, Apolipoprotein E, and Solute Carrier Organic Anion Genetic Variants with Atorvastatin Response among Jordanian Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors.
Diabetes Mellitus, Type 2
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Diabetes Mellitus, Type 2
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Diabetes Mellitus, Type 2
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
Diabetes Mellitus, Type 2
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Diabetes Mellitus, Type 2
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
Diabetes Mellitus, Type 2
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Diabetes Mellitus, Type 2
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Diabetic Angiopathies
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Diabetic Nephropathies
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Diabetic Nephropathies
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Diabetic Nephropathies
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Diabetic Nephropathies
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Diabetic Nephropathies
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
Diabetic Nephropathies
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.
Diabetic Nephropathies
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Diabetic Nephropathies
Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy.
Diabetic Nephropathies
Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.
Diabetic Nephropathies
Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats.
Diabetic Nephropathies
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Diabetic Neuropathies
Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
Diabetic Retinopathy
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Diabetic Retinopathy
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Diabetic Retinopathy
High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Diabetic Retinopathy
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Diabetic Retinopathy
Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.
Drug Eruptions
Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Drug-Related Side Effects and Adverse Reactions
Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.
Drug-Related Side Effects and Adverse Reactions
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
Drug-Related Side Effects and Adverse Reactions
HMG-CoA reductase inhibitors and myotoxicity.
Drug-Related Side Effects and Adverse Reactions
HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.
Drug-Related Side Effects and Adverse Reactions
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Drug-Related Side Effects and Adverse Reactions
Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.
Drug-Related Side Effects and Adverse Reactions
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Dwarfism
Altering potato isoprenoid metabolism increases biomass and induces early flowering.
Dyskinesias
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Dyslipidemias
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Dyslipidemias
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Dyslipidemias
A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin.
Dyslipidemias
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
Dyslipidemias
A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
Dyslipidemias
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
Dyslipidemias
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Dyslipidemias
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
Dyslipidemias
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
Dyslipidemias
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Dyslipidemias
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Dyslipidemias
Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine.
Dyslipidemias
Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells.
Dyslipidemias
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Dyslipidemias
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Dyslipidemias
Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.
Dyslipidemias
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Dyslipidemias
Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase.
Dyslipidemias
Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
Dyslipidemias
Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients.
Dyslipidemias
Dyslipidemias in diabetic patients. Is standard cholesterol treatment appropriate?
Dyslipidemias
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Dyslipidemias
Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Dyslipidemias
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Dyslipidemias
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Dyslipidemias
Effects of prickly pear dried leaves, artichoke leaves, turmeric and garlic extracts, and their combinations on preventing dyslipidemia in rats.
Dyslipidemias
Effects of Talinum triangulare leaf flavonoid extract on streptozotocin-induced hyperglycemia and associated complications in rats.
Dyslipidemias
Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
Dyslipidemias
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Dyslipidemias
Genetic Contribution of Variants near SORT1 and APOE on LDL Cholesterol Independent of Obesity in Children.
Dyslipidemias
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Dyslipidemias
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
Dyslipidemias
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
Dyslipidemias
High-Efficacy ?,?-Dehydromonacolin S Improves Hepatic Steatosis and Suppresses Gluconeogenesis Pathway in High-Fat Diet-Induced Obese Rats.
Dyslipidemias
Human proximal tubular epithelium actively secretes but does not retain rosuvastatin.
Dyslipidemias
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Dyslipidemias
Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells.
Dyslipidemias
Investigations of statins in heart failure: inflammatory biomarkers and hormones.
Dyslipidemias
Medicinal plants and bioactive natural compounds as inhibitors of HMG-CoA reductase: A literature review.
Dyslipidemias
Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Dyslipidemias
Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
Dyslipidemias
Novel Phenoxazinones as potent agonist of PPAR-?: design, synthesis, molecular docking and in vivo studies.
Dyslipidemias
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Dyslipidemias
Pharmacokinetic and pharmacodynamic interaction of Rosuvastatin calcium with guggulipid extract in rats.
Dyslipidemias
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
Dyslipidemias
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Dyslipidemias
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Dyslipidemias
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Dyslipidemias
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Dyslipidemias
Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.
Dyslipidemias
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Dyslipidemias
Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Dyslipidemias
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Dyslipidemias
Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Dyslipidemias
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Dyslipidemias
Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.
Dyslipidemias
Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin.
Dyslipidemias
Simvastatin evokes an unpredicted inhibition of ?-adrenoceptor-mediated vasodilatation in porcine coronary artery.
Dyslipidemias
Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
Dyslipidemias
Statins in oncological research: from experimental studies to clinical practice.
Dyslipidemias
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
Dyslipidemias
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
Dyslipidemias
The interaction of fluvastatin and cyclosporin A in renal transplant patients.
Dyslipidemias
The potential behavioral and economic impacts of widespread HMG-CoA reductase inhibitor (statin) use.
Dyslipidemias
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Dyslipidemias
The Risk of Rosacea According to Chronic Diseases and Medications: A 5-Year Retrospective, Multi-Institutional Case-Control Study.
Dyslipidemias
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Dyslipidemias
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia.
Dyslipidemias
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Dyslipidemias
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]
Dyslipidemias
[Effect of the brand and generic medicine of pravastatin on dyslipidemia in rabbits fed a high cholesterol diet]
Dyslipidemias
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
Dyslipidemias
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance]
Encephalomyelitis
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Encephalomyelitis
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Encephalomyelitis
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Encephalomyelitis
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Encephalomyelitis, Autoimmune, Experimental
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Encephalomyelitis, Autoimmune, Experimental
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Endometrial Neoplasms
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Endometriosis
Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.
Eosinophilia
Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia.
Ependymoma
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Epilepsy
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Epilepsy
The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy.
Erectile Dysfunction
HMG CoA Reductase Inhibitors and Impotence: Two Case Series from the Spanish and French Drug Monitoring Systems.
Esophageal Squamous Cell Carcinoma
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Esophageal Squamous Cell Carcinoma
SREBP2 is upregulated in esophageal squamous cell carcinoma and co?operates with c?Myc to regulate HMGCR expression.
Essential Hypertension
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Essential Hypertension
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Essential Hypertension
Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study.
Essential Hypertension
Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension.
Essential Hypertension
Functional promoter polymorphisms govern differential expression of HMG-CoA reductase gene in mouse models of essential hypertension.
Exanthema
Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
Exanthema
[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies].
Eye Diseases
Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases.
Fatigue Syndrome, Chronic
Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis.
Fatty Liver
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Fatty Liver
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Fatty Liver
Inhibition of Adenosine Monophosphate-Activated Protein Kinase-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholesterolemia and Promotes Hepatic Steatosis and Insulin Resistance.
Fatty Liver
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Fatty Liver
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Fatty Liver
Pyrazinamide alleviates rifampin-induced steatohepatitis in mice by regulating the activities of cholesterol-activated 7?-hydroxylase and lipoprotein lipase.
Fatty Liver
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Fatty Liver
Rice bran enzymatic extract reduces atherosclerotic plaque development and steatosis in high-fat fed ApoE-/- mice.
Fatty Liver
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
Fatty Liver
Suppression of hepatic HMG-CoA reductase activity by beta-muricholic acid in mice fed a diet containing cholesterol and cholic acid.
Fatty Liver
[Study on lipid-lowering mechanism of active peptide DP17 from Eupolyphaga steleophaga in hyperlipidemia rats].
Fatty Liver, Alcoholic
Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.
Fibrosarcoma
Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells.
Gallstones
3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme.
Gallstones
Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice.
Gallstones
Antilithiasic effect of beta-cyclodextrin in LPN hamster: comparison with cholestyramine.
Gallstones
Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid.
Gallstones
Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment.
Gallstones
Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse.
Gallstones
Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects.
Gallstones
Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
Gallstones
Effect of chenodeoxycholic acid and phenobarbital on the rate-limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones.
Gallstones
Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
Gallstones
Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Gallstones
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
Gallstones
Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
Gallstones
Hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in hamsters on a lithogenic diet.
Gallstones
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Gallstones
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
Gallstones
Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones.
Gallstones
Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Gallstones
Hepatic cholesterol metabolism in patients with cholesterol gallstones: enhanced intracellular transport of cholesterol.
Gallstones
Hepatic expression of cholesterol regulating genes favour increased circulating low-density lipoprotein in HIV infected patients with gallstone disease: a preliminary study.
Gallstones
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Gallstones
Hepatic microsomal activities of cholesterol 7 alpha-hydroxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in the prairie dog. An animal model for cholesterol gallstone disease.
Gallstones
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Gallstones
Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis.
Gallstones
Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
Gallstones
Protective Effects of Yinchenhao Decoction on Cholesterol Gallstone in Mice Fed a Lithogenic Diet by Regulating LXR, CYP7A1, CYP7B1, and HMGCR Pathways.
Gallstones
Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients.
Gallstones
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Gallstones
Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
Gallstones
Therapeutic Reflections In Cholesterol Homeostasis And Gallstone Disease. A Review.
Gallstones
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Gallstones
[Experimental study on hepatic HMG-CoA reductase activity in relation to the formation and dissolution of cholesterol gallstones (author's transl)]
Gastroesophageal Reflux
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Glaucoma
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Glioblastoma
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Glioblastoma
HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model.
Glioblastoma
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Glioblastoma
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Glioma
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
Glioma
In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.
Glioma
Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?
Glioma
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Glioma
Regulation of sterol synthesis and of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lipoproteins in glial cells in primary culture.
Glioma
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Glomerulonephritis
Effect of simvastatin on proliferative nephritis and cell-cycle protein expression.
Glomerulonephritis
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Glomerulonephritis, IGA
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.
Glomerulonephritis, IGA
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy.
Glomerulonephritis, Membranous
Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Glucose Intolerance
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Glucose Intolerance
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Glucose Intolerance
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Glucose Intolerance
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Glucosephosphate Dehydrogenase Deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Goiter
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway.
Graft vs Host Disease
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
Graft vs Host Disease
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
Graft vs Host Disease
Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Gynecomastia
Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature.
Hearing Loss, Sensorineural
Possible role of HMG-CoA reductase inhibitors for the treatment of sudden sensorineural hearing loss (SSHL).
Heart Diseases
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Heart Diseases
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Heart Diseases
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Heart Diseases
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
Heart Diseases
[Early statin treatment in acute coronary syndrome. Is this evidence-based?]
Heart Failure
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Heart Failure
Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure.
Heart Failure
Case Report: Immune Mediated Necrotizing Myopathy With IgG Antibodies to 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase (HMGCR) May Present With Acute Systolic Heart Failure.
Heart Failure
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Heart Failure
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
Heart Failure
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
Heart Failure
Impact of Statin Therapy on Clinical Outcomes in Chronic Heart Failure Patients According to Beta-Blocker Use: Results of CIBIS II.
Heart Failure
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Heart Failure
Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure.
Heart Failure
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Heart Failure
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Heart Failure
Provider adherence to clinical guidelines related to lipid-lowering medications.
Heart Failure
Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
Heart Failure
Simvastatin normalizes autonomic neural control in experimental heart failure.
Heart Failure
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Heart Failure
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Heart Failure
Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure.
Heart Failure
The nutritional and metabolic support of heart failure in the intensive care unit.
Heart Failure
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Heart Failure, Systolic
Case Report: Immune Mediated Necrotizing Myopathy With IgG Antibodies to 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase (HMGCR) May Present With Acute Systolic Heart Failure.
Heart Failure, Systolic
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Hemangioma, Cavernous, Central Nervous System
The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway.
Hematologic Neoplasms
HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
Hematologic Neoplasms
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Hemorrhagic Stroke
Prevention of stroke and dementia with statins: Effects beyond lipid lowering.
Hepatitis
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
Hepatitis
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]
Hepatitis C
Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Hepatitis C
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Hepatitis C
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Hepatitis, Autoimmune
HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis.
Hepatoblastoma
Growth requirements and expression of LDL receptor and HMG-CoA reductase in Hep G2 hepatoblastoma cells cultured in a chemically defined medium.
Hepatoblastoma
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Hepatoblastoma
The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
Hepatoblastoma
The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells.
Herpes Zoster
Differential ACTH response of immunodetectable HMG CoA reductase and cytochromes P450(17 alpha) and P450(21) in guinea pig adrenal outer zone cell types, zona glomerulosa and zona fasciculata.
Histiocytoma, Malignant Fibrous
Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
HIV Infections
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
HIV Infections
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Homozygous Familial Hypercholesterolemia
Biologically active low density lipoprotein in human peripheral lymph.
Homozygous Familial Hypercholesterolemia
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Homozygous Familial Hypercholesterolemia
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Homozygous Familial Hypercholesterolemia
Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.
Homozygous Familial Hypercholesterolemia
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and the esterification of cholesterol in human long term lymphoid cell lines.
Homozygous Familial Hypercholesterolemia
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Huntington Disease
Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease.
Hyperalgesia
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Hyperalgesia
RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice.
Hypercholesterolemia
'Muscle-sparing' statins: preclinical profiles and future clinical use.
Hypercholesterolemia
3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS.
Hypercholesterolemia
3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia?
Hypercholesterolemia
3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.
Hypercholesterolemia
A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5.
Hypercholesterolemia
A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Hypercholesterolemia
A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
Hypercholesterolemia
A controlled trial of pravastatin vs probucol in the treatment of primary hypercholesterolemia.
Hypercholesterolemia
A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
Hypercholesterolemia
A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway.
Hypercholesterolemia
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Hypercholesterolemia
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hypercholesterolemia
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
Hypercholesterolemia
A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
Hypercholesterolemia
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism.
Hypercholesterolemia
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Hypercholesterolemia
Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression.
Hypercholesterolemia
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Hypercholesterolemia
Adverse effects of long-term exposure to bisphenol A during adulthood leading to hyperglycaemia and hypercholesterolemia in mice.
Hypercholesterolemia
Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective).
Hypercholesterolemia
An In Vitro and Molecular Informatics Study to Evaluate the Antioxidative and ?-hydroxy-?-methylglutaryl-CoA Reductase Inhibitory Property of Ficus virens Ait.
Hypercholesterolemia
Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia.
Hypercholesterolemia
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Hypercholesterolemia
Antihypercholesterolemic and antiatherosclerotic potencies of Pandanus tectorius fruits via increasing scavenger receptor-B1 genes expression and inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Hypercholesterolemia
Astragalus polysaccharides lowers plasma cholesterol through mechanisms distinct from statins.
Hypercholesterolemia
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Hypercholesterolemia
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Hypercholesterolemia
Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.
Hypercholesterolemia
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Hypercholesterolemia
Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway.
Hypercholesterolemia
Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia.
Hypercholesterolemia
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Hypercholesterolemia
Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
Hypercholesterolemia
Biphasic influence of pravastatin on human cardiac microvascular endothelial cell functions under pathological and physiological conditions.
Hypercholesterolemia
Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia.
Hypercholesterolemia
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
Hypercholesterolemia
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Hypercholesterolemia
Caloric restrictions affect some factors involved in age-related hypercholesterolemia.
Hypercholesterolemia
Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
Hypercholesterolemia
Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Hypercholesterolemia
Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Hypercholesterolemia
Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.
Hypercholesterolemia
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Hypercholesterolemia
Cholesterol and bile acid synthesis during total parenteral nutrition with and without lipid emulsion in the rat.
Hypercholesterolemia
Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
Hypercholesterolemia
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
Hypercholesterolemia
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.
Hypercholesterolemia
Chronokinetics of Pravastatin Administered in the PM Compared with AM Dosing.
Hypercholesterolemia
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
Hypercholesterolemia
Collision-induced dissociation of the negative ions of simvastatin hydroxy acid and related species.
Hypercholesterolemia
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Hypercholesterolemia
Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
Hypercholesterolemia
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Hypercholesterolemia
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hypercholesterolemia
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
Hypercholesterolemia
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Hypercholesterolemia
Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
Hypercholesterolemia
Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins.
Hypercholesterolemia
Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
Hypercholesterolemia
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Hypercholesterolemia
Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.
Hypercholesterolemia
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Hypercholesterolemia
Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization.
Hypercholesterolemia
Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
Hypercholesterolemia
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Hypercholesterolemia
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Hypercholesterolemia
Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice.
Hypercholesterolemia
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
Hypercholesterolemia
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Hypercholesterolemia
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
Hypercholesterolemia
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution.
Hypercholesterolemia
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Hypercholesterolemia
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Hypercholesterolemia
Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin.
Hypercholesterolemia
Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
Hypercholesterolemia
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Hypercholesterolemia
Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.
Hypercholesterolemia
Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study.
Hypercholesterolemia
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Hypercholesterolemia
Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients.
Hypercholesterolemia
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Hypercholesterolemia
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Hypercholesterolemia
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Hypercholesterolemia
Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
Hypercholesterolemia
Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
Hypercholesterolemia
Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Hypercholesterolemia
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Hypercholesterolemia
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Hypercholesterolemia
Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia.
Hypercholesterolemia
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Hypercholesterolemia
Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits.
Hypercholesterolemia
Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group.
Hypercholesterolemia
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Hypercholesterolemia
Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.
Hypercholesterolemia
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Hypercholesterolemia
Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.
Hypercholesterolemia
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Hypercholesterolemia
Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia.
Hypercholesterolemia
Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia.
Hypercholesterolemia
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Hypercholesterolemia
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
Hypercholesterolemia
Efficacy and short-term effects of pravastatin, a potent inhibitor of HMG-Co A reductase, on hypercholesterolemia in climacteric women.
Hypercholesterolemia
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Hypercholesterolemia
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Hypercholesterolemia
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
Hypercholesterolemia
Endothelium modulates contractile response to simvastatin in rat aorta.
Hypercholesterolemia
Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet.
Hypercholesterolemia
Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form.
Hypercholesterolemia
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Hypercholesterolemia
Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
Hypercholesterolemia
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Hypercholesterolemia
Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia.
Hypercholesterolemia
Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Hypercholesterolemia
Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
Hypercholesterolemia
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
Hypercholesterolemia
Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
Hypercholesterolemia
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Hypercholesterolemia
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Hypercholesterolemia
Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin.
Hypercholesterolemia
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
Hypercholesterolemia
HMG CoA reductase inhibitors: new horizons in the management of hypercholesteremia. XIth Congress of the European Society of Cardiology. Nice, France, September 10-14, 1989.
Hypercholesterolemia
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
Hypercholesterolemia
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
Hypercholesterolemia
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Hypercholesterolemia
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.
Hypercholesterolemia
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Hypercholesterolemia
HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia.
Hypercholesterolemia
HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia.
Hypercholesterolemia
HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
Hypercholesterolemia
HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
Hypercholesterolemia
Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats.
Hypercholesterolemia
Hypercholesterolemia of copper deficiency is linked to glutathione metabolism and regulation of hepatic HMG-CoA reductase.
Hypercholesterolemia
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Hypercholesterolemia
Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors.
Hypercholesterolemia
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Hypercholesterolemia
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Hypercholesterolemia
Increased rate of cholesterologenesis--a possible cause of hypercholesterolemia in experimental chronic renal failure in rats.
Hypercholesterolemia
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Hypercholesterolemia
Increased superoxide anion production by platelets in hypercholesterolemic patients.
Hypercholesterolemia
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Hypercholesterolemia
Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2).
Hypercholesterolemia
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Hypercholesterolemia
Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity.
Hypercholesterolemia
Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin's toxicity in rat skeletal myofibers.
Hypercholesterolemia
Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.
Hypercholesterolemia
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
Hypercholesterolemia
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Hypercholesterolemia
Involvement of interleukin-1 in lead nitrate-induced hypercholesterolemia in mice.
Hypercholesterolemia
Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier.
Hypercholesterolemia
Is there a role for the adrenals in the development of hypercholesterolemia in Zucker fatty rats?
Hypercholesterolemia
Isorhamnetin derivatives and piscidic acid for hypercholesterolemia: cholesterol permeability, HMG-CoA reductase inhibition, and docking studies.
Hypercholesterolemia
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Hypercholesterolemia
LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand.
Hypercholesterolemia
Lead nitrate-induced development of hypercholesterolemia in rats: sterol-independent gene regulation of hepatic enzymes responsible for cholesterol homeostasis.
Hypercholesterolemia
Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia.
Hypercholesterolemia
Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis.
Hypercholesterolemia
Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia.
Hypercholesterolemia
Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
Hypercholesterolemia
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Hypercholesterolemia
Lovastatin production: From molecular basis to industrial process optimization.
Hypercholesterolemia
Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway.
Hypercholesterolemia
Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.
Hypercholesterolemia
Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Hypercholesterolemia
Management of hyperlipidemia: goals for the prevention of atherosclerosis.
Hypercholesterolemia
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Hypercholesterolemia
Mevalonate cascade and its regulation in cholesterol metabolism in different tissue in health and disease.
Hypercholesterolemia
Mikania micrantha Extract Inhibits HMG-CoA Reductase and ACAT2 and Ameliorates Hypercholesterolemia and Lipid Peroxidation in High Cholesterol-Fed Rats.
Hypercholesterolemia
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
Hypercholesterolemia
Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase gene expression by CuZn superoxide dismutase in human fibroblasts and HepG2 cells.
Hypercholesterolemia
Modulation of hypercholesterolemia-induced alterations in apolipoprotein B and HMG-CoA reductase expression by selenium supplementation.
Hypercholesterolemia
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.
Hypercholesterolemia
New drugs for treating hypercholesterolemia and other hyperlipidaemias--the HMG CoA reductase inhibitors.
Hypercholesterolemia
New insights into the genetic regulation of intestinal cholesterol absorption.
Hypercholesterolemia
Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
Hypercholesterolemia
Nutrition classics. Proceedings of the National Academy of Sciences of the United States of America, Volume 71, 1974: Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. By Michael S. Brown and Joseph L. Goldstein.
Hypercholesterolemia
Omega-3 as well as caloric restriction prevent the age-related modifications of cholesterol metabolism.
Hypercholesterolemia
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Hypercholesterolemia
Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice.
Hypercholesterolemia
Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice.
Hypercholesterolemia
Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers.
Hypercholesterolemia
Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
Hypercholesterolemia
Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.
Hypercholesterolemia
Phytoconstituents of an ethanolic pod extract of Prosopis cineraria triggers the inhibition of HMG-CoA reductase and the regression of atherosclerotic plaque in hypercholesterolemic rabbits.
Hypercholesterolemia
Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells.
Hypercholesterolemia
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Hypercholesterolemia
Plasma and thrombocyte levels of coenzyme Q10 in children with Smith-Lemli-Opitz syndrome (SLOS) and the influence of HMG-CoA reductase inhibitors.
Hypercholesterolemia
Plasma lipoproteins and cholesterol metabolism in Yoshida rats: an animal model of spontaneous hyperlipemia.
Hypercholesterolemia
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Hypercholesterolemia
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Hypercholesterolemia
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Hypercholesterolemia
Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity.
Hypercholesterolemia
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
Hypercholesterolemia
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Hypercholesterolemia
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Hypercholesterolemia
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways.
Hypercholesterolemia
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Hypercholesterolemia
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Hypercholesterolemia
Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis.
Hypercholesterolemia
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Hypercholesterolemia
Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia.
Hypercholesterolemia
Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Hypercholesterolemia
Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Hypercholesterolemia
Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Hypercholesterolemia
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Hypercholesterolemia
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Hypercholesterolemia
Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.
Hypercholesterolemia
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Hypercholesterolemia
Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras.
Hypercholesterolemia
Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Hypercholesterolemia
Simvastatin increases excitability in the hippocampus via a PI3 kinase-dependent mechanism.
Hypercholesterolemia
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3? phosphorylation.
Hypercholesterolemia
Simvastatin inhibits glucose metabolism and legumain activity in human myotubes.
Hypercholesterolemia
Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells.
Hypercholesterolemia
Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia.
Hypercholesterolemia
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Hypercholesterolemia
Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation.
Hypercholesterolemia
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Hypercholesterolemia
Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.
Hypercholesterolemia
Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content.
Hypercholesterolemia
Statin-mediated cholesterol depletion exerts coordinated effects on the alterations in rat vascular smooth muscle cell biomechanics and migration.
Hypercholesterolemia
Statins and renal diseases: from primary prevention to renal replacement therapy.
Hypercholesterolemia
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Hypercholesterolemia
Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway.
Hypercholesterolemia
Stimulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by o,p'-DDD.
Hypercholesterolemia
Structure-Based Design and Screen of Novel Inhibitors for Class II 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Streptococcus Pneumoniae.
Hypercholesterolemia
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Hypercholesterolemia
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Hypercholesterolemia
Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease.
Hypercholesterolemia
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Hypercholesterolemia
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Hypercholesterolemia
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Hypercholesterolemia
The antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer prevention.
Hypercholesterolemia
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
Hypercholesterolemia
The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
Hypercholesterolemia
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
Hypercholesterolemia
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.
Hypercholesterolemia
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
Hypercholesterolemia
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Hypercholesterolemia
The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia.
Hypercholesterolemia
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.
Hypercholesterolemia
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Hypercholesterolemia
Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
Hypercholesterolemia
Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy.
Hypercholesterolemia
Thyroid-Stimulating Hormone Decreases HMG-CoA Reductase Phosphorylation via AMP-Activated Protein Kinase in the liver.
Hypercholesterolemia
Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Hypercholesterolemia
Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin.
Hypercholesterolemia
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Hypercholesterolemia
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Hypercholesterolemia
Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
Hypercholesterolemia
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Hypercholesterolemia
[A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia]
Hypercholesterolemia
[Cholesterol absorption as a target for the treatment of hypercholesterolemia]
Hypercholesterolemia
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
Hypercholesterolemia
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]
Hypercholesterolemia
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]
Hypercholesterolemia
[Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]
Hypercholesterolemia
[HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]
Hypercholesterolemia
[Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)]
Hypercholesterolemia
[Lipid status and basal steroid hormone level following 16 weeks of lovastatin therapy in primary hypercholesterolemia]
Hypercholesterolemia
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
Hypercholesterolemia
[New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors]
Hypercholesterolemia
[New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]
Hypercholesterolemia
[Personal experience with lovastatin, a HMG-CoA reductase inhibitor (Mevacor, MSD) in the treatment of hypercholesterolemia]
Hypercholesterolemia
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Hypercholesterolemia
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
Hypercholesterolemia
[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia]
Hypercholesterolemia
[The effects of plasma cholesterol reduction on vasoconstriction due to sympathetic activation in patients with moderate primary hypercholesterolemia]
Hypercholesterolemia
[The long-term effect of HMG-CoA reductase inhibitor to the hypercholesterolemia in the climacterium and its endocrinological change]
Hypercholesterolemia
[Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up]
Hyperglycemia
?-Cell-Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of ?-Cell Mass and Impaired Insulin Secretion.
Hyperglycemia
Effects of Talinum triangulare leaf flavonoid extract on streptozotocin-induced hyperglycemia and associated complications in rats.
Hyperglycemia
Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications.
Hyperglycemia
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Hyperglycemia
Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.
Hyperglycemia
The Effect of Statins on the No-Reflow Phenomenon: An Observational Study in Patients with Hyperglycemia before Primary Angioplasty.
Hyperhomocysteinemia
Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin.
Hyperhomocysteinemia
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
Hyperinsulinism
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Hyperinsulinism
Hexosamine Biosynthesis Impairs Insulin Action via a Cholesterolgenic Response.
Hyperinsulinism
Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice.
Hyperlipidemia, Familial Combined
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Hyperlipidemia, Familial Combined
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Hyperlipidemia, Familial Combined
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Hyperlipidemias
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Hyperlipidemias
A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin.
Hyperlipidemias
A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats.
Hyperlipidemias
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Hyperlipidemias
Antihyperlipidemic and Hepatoprotective Properties of Vitamin B6 Supplementation in Rats with High-Fat Diet-Induced Hyperlipidemia.
Hyperlipidemias
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Hyperlipidemias
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
Hyperlipidemias
Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.
Hyperlipidemias
Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
Hyperlipidemias
Beneficial Effects of SREBP Decoy Oligodeoxynucleotide in an Animal Model of Hyperlipidemia.
Hyperlipidemias
Cassia auriculata flower extract attenuates hyperlipidemia in male Wistar rats by regulating the hepatic cholesterol metabolism.
Hyperlipidemias
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Hyperlipidemias
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Hyperlipidemias
Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
Hyperlipidemias
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Hyperlipidemias
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
Hyperlipidemias
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
Hyperlipidemias
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Hyperlipidemias
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Hyperlipidemias
Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.
Hyperlipidemias
Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
Hyperlipidemias
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Hyperlipidemias
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
Hyperlipidemias
Effect of geraniol, a plant derived monoterpene on lipids and lipid metabolizing enzymes in experimental hyperlipidemic hamsters.
Hyperlipidemias
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Hyperlipidemias
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Hyperlipidemias
Effect of in utero exposure of Toddy (coconut palm wine) on liver function and lipid metabolism in rat fetuses.
Hyperlipidemias
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
Hyperlipidemias
Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
Hyperlipidemias
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Hyperlipidemias
Effect of the polyphenol-rich extract from Allium cepa on hyperlipidemic sprague-dawley rats.
Hyperlipidemias
Effects of an HMG-CoA reductase inhibitor, pravastatin, and bile sequestering resin, cholestyramine, on plasma plant sterol levels in hypercholesterolemic subjects.
Hyperlipidemias
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Hyperlipidemias
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Hyperlipidemias
Effects of Honey on Postprandial Hyperlipidemia and Oxidative Stress in Wistar Rats: Role of HMG-CoA Reductase Inhibition and Antioxidant Effect.
Hyperlipidemias
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Hyperlipidemias
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Hyperlipidemias
Effects of oral selenium and magnesium co-supplementation on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in rats fed a high-fat diet.
Hyperlipidemias
Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
Hyperlipidemias
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Hyperlipidemias
Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia.
Hyperlipidemias
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Hyperlipidemias
Energy replacement using glucose does not increase postprandial lipemia after moderate intensity exercise.
Hyperlipidemias
Evaluation of DNA damage in Wistar rat tissues with hyperlipidemia induced by tyloxapol.
Hyperlipidemias
Extracellular and Intracellular Polysaccharide Extracts of Trametes versicolor Improve Lipid Profiles Via Serum Regulation of Lipid-Regulating Enzymes in Hyperlipidemic Mice.
Hyperlipidemias
Extract of Wax Gourd Peel Prevents High-Fat Diet-Induced Hyperlipidemia in C57BL/6 Mice via the Inhibition of the PPAR? Pathway.
Hyperlipidemias
Ezetimibe in Renal Transplant Patients with Hyperlipidemia Resistant to HMG-CoA Reductase Inhibitors.
Hyperlipidemias
Fabrication and Appraisal of Simvastatin via Tailored Niosomal Nanovesicles for Transdermal Delivery Enhancement: In Vitro and In Vivo Assessment.
Hyperlipidemias
Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
Hyperlipidemias
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Hyperlipidemias
HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells.
Hyperlipidemias
HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.
Hyperlipidemias
HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia.
Hyperlipidemias
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors.
Hyperlipidemias
Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.
Hyperlipidemias
Improvement of hyperlipidemia by aerobic exercise in mice through a regulatory effect of miR-21a-5p on its target genes.
Hyperlipidemias
Influence of large molecular polymeric pigments isolated from fermented Zijuan tea on the activity of key enzymes involved in lipid metabolism in rat.
Hyperlipidemias
Interactive and Multifactorial Mechanisms of Calcific Vascular and Valvular Disease.
Hyperlipidemias
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Hyperlipidemias
Kakkalide and irisolidone: HMG-CoA reductase inhibitors isolated from the flower of Pueraria thunbergiana.
Hyperlipidemias
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Hyperlipidemias
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Hyperlipidemias
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Hyperlipidemias
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Hyperlipidemias
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
Hyperlipidemias
Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice.
Hyperlipidemias
Methanolic Extract of Piper sarmentosum Attenuates Obesity and Hyperlipidemia in Fructose-Induced Metabolic Syndrome Rats.
Hyperlipidemias
Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions.
Hyperlipidemias
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
Hyperlipidemias
Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers.
Hyperlipidemias
Pharmacological cholesterol depletion disturbs ciliogenesis and ciliary function in developing zebrafish.
Hyperlipidemias
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Hyperlipidemias
Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
Hyperlipidemias
Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
Hyperlipidemias
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus.
Hyperlipidemias
Prenatal exposure of an alcoholic beverage (Arrack) on fetal lipid metabolism in rats.
Hyperlipidemias
Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats.
Hyperlipidemias
Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats.
Hyperlipidemias
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in taiwan.
Hyperlipidemias
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Hyperlipidemias
Rice bran enzymatic extract reduces atherosclerotic plaque development and steatosis in high-fat fed ApoE-/- mice.
Hyperlipidemias
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Hyperlipidemias
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Hyperlipidemias
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Hyperlipidemias
Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4.
Hyperlipidemias
Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient.
Hyperlipidemias
Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.
Hyperlipidemias
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
Hyperlipidemias
The effects of pravastatin on hyperlipidemia in renal transplant recipients.
Hyperlipidemias
The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
Hyperlipidemias
The spectrum of statin hepatotoxicity: Experience of the drug induced liver injury network.
Hyperlipidemias
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
Hyperlipidemias
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Hyperlipidemias
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Hyperlipidemias
Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.
Hyperlipidemias
Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application.
Hyperlipidemias
Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study.
Hyperlipidemias
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]
Hyperlipidemias
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
Hyperlipidemias
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]
Hyperlipidemias
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]
Hyperlipidemias
[Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
Hyperlipidemias
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Hyperlipidemias
[Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study]
Hyperlipidemias
[Study on anti-hyperlipidemia mechanism of high frequency herb pairs by molecular docking method].
Hyperlipidemias
[Study on lipid-lowering traditional Chinese medicines based on pharmacophore technology and patent retrieval].
Hyperlipoproteinemia Type II
Abnormal induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase in leukocytes from subjects with heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Hyperlipoproteinemia Type II
Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
Hyperlipoproteinemia Type II
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Hyperlipoproteinemia Type II
Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Hyperlipoproteinemia Type II
Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Hyperlipoproteinemia Type II
Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol.
Hyperlipoproteinemia Type II
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Hyperlipoproteinemia Type II
Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Hyperlipoproteinemia Type II
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Hyperlipoproteinemia Type II
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
Hyperlipoproteinemia Type II
Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Hyperlipoproteinemia Type II
Metabolism of low-density lipoproteins by cultured hepatocytes from normal and homozygous familial hypercholesterolemic subjects.
Hyperlipoproteinemia Type II
Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Nutrition classics. Proceedings of the National Academy of Sciences of the United States of America, Volume 71, 1974: Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. By Michael S. Brown and Joseph L. Goldstein.
Hyperlipoproteinemia Type II
Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Hyperlipoproteinemia Type II
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
Hyperlipoproteinemia Type II
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Hyperlipoproteinemia Type II
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
Hyperlipoproteinemia Type II
Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Hyperlipoproteinemia Type II
Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
Hyperlipoproteinemia Type II
The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.
Hyperlipoproteinemia Type II
The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia Type II
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Hyperlipoproteinemia Type II
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Hyperlipoproteinemia Type II
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.
Hyperlipoproteinemia Type II
Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.
Hyperlipoproteinemia Type II
Use of mutant fibroblasts in the analysis of the regulation of cholesterol metabolism in human cells.
Hyperlipoproteinemia Type II
[Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia]
Hyperlipoproteinemia Type II
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia]
Hyperlipoproteinemia Type II
[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy]
Hyperlipoproteinemia Type II
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences]
Hyperlipoproteinemia Type II
[Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia]
Hyperlipoproteinemia Type III
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Hyperlipoproteinemias
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in the human gastrointestinal tract.
Hyperlipoproteinemias
Chronic treatment with fluvastatin improves smooth muscle dilatory function in genetically determined hyperlipoproteinemia.
Hyperlipoproteinemias
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Hyperlipoproteinemias
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia.
Hyperlipoproteinemias
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Hyperlipoproteinemias
HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia.
Hyperlipoproteinemias
Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
Hyperlipoproteinemias
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Hyperlipoproteinemias
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Hyperpigmentation
Artemisinic acid inhibits melanogenesis through downregulation of C/EBP ?-dependent expression of HMG-CoA reductase gene.
Hypersensitivity
Drug Allergies Documented in Electronic Health Records of a Large Healthcare System.
Hypersensitivity
Pleiotropic phenotypes caused by an opal nonsense mutation in an essential gene encoding HMG-CoA reductase in fission yeast.
Hypersensitivity
[Polymyositis induced or associated with lipid-lowering drugs: five cases]
Hypertension
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
Hypertension
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
Hypertension
An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat.
Hypertension
Anomalous AMPK-regulated angiotensin AT1R expression and SIRT1-mediated mitochondrial biogenesis at RVLM in hypertension programming of offspring to maternal high fructose exposure.
Hypertension
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Hypertension
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Hypertension
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Hypertension
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Hypertension
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Hypertension
Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension.
Hypertension
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Hypertension
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
Hypertension
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
Hypertension
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Hypertension
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Hypertension
Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway.
Hypertension
Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population.
Hypertension
Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model.
Hypertension
Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Hypertension
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
Hypertension
Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center.
Hypertension
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
Hypertension
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Hypertension
Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress.
Hypertension
Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Hypertension
The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia.
Hypertension
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Hypertension
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Hypertension
[Prevention of the manifestation of diabetes in the elderly in the presymptomatic stage]
Hypertension
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Hypertension, Pulmonary
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Hypertension, Pulmonary
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Hypertension, Pulmonary
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Hypertension, Pulmonary
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase.
Hypertension, Pulmonary
Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21(WAF1).
Hypertension, Pulmonary
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Hypertension, Pulmonary
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Hypertriglyceridemia
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Hypertriglyceridemia
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Hypertriglyceridemia
Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors.
Hypertriglyceridemia
Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
Hypertriglyceridemia
Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
Hypertriglyceridemia
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Hypertriglyceridemia
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Hypertriglyceridemia
HMG-CoA reductase activity in the liver of rats with hereditary hypertriglyceridemia: effect of dietary fish oil.
Hypertriglyceridemia
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Hypertriglyceridemia
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Hypertriglyceridemia
Insulin deficiency alters cellular cholesterol metabolism in murine macrophages.
Hypertriglyceridemia
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways.
Hypertriglyceridemia
Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts.
Hypertriglyceridemia
The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
Hypertriglyceridemia
[Goals and practical implementation of lipid therapy in coronary heart disease]
Hypertriglyceridemia
[Treatment for dyslipidemia--a strategy for the prevention of atherosclerosis].
Hypoalbuminemia
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Hypoglycemia
Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes.
Hypotension
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
Hypothyroidism
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism.
Hypothyroidism
HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism.
Hypothyroidism
The effect of hypothyroidism and thyroxine replacement on hepatic and intestinal HMG-CoA reductase and ACAT activities and biliary lipids in the rat.
Idiopathic Pulmonary Fibrosis
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Infarction, Middle Cerebral Artery
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Infarction, Middle Cerebral Artery
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Infarction, Middle Cerebral Artery
Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion.
Infections
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Infections
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Infections
Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.
Infections
Both ganglioside GM2 and cholesterol in the cell membrane are essential for Bombyx mori cypovirus cell entry.
Infections
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Infections
Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.
Infections
DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target.
Infections
Differential induction and suppression of potato 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in response to Phytophthora infestans and to its elicitor arachidonic acid.
Infections
Down-regulation of single-stranded DNA-binding protein 1 expression induced by HCMV infection promotes lipid accumulation in cells.
Infections
Effect of atovastatin treatment on porcine circovirus 2 infection in BALB/c mice.
Infections
Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters.
Infections
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
Infections
HMG CoA reductase is negatively associated with PCV2 infection and PCV2-induced apoptotic cell death.
Infections
HMGCR inhibits the early stage of PCV2 infection, while PKC enhances the infection at the late stage.
Infections
HmgR, a key enzyme in the mevalonate pathway for isoprenoid biosynthesis, is essential for growth of Listeria monocytogenes EGDe.
Infections
Human parainfluenza virus type 1 regulates cholesterol biosynthesis and establishes quiescent infection in human airway cells.
Infections
Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin.
Infections
Intestinal Epithelial Cells and the Microbiome Undergo Swift Reprogramming at the Inception of Colonic Citrobacter rodentium Infection.
Infections
Lipid-derived signals that discriminate wound- and pathogen-responsive isoprenoid pathways in plants: methyl jasmonate and the fungal elicitor arachidonic acid induce different 3-hydroxy-3-methylglutaryl-coenzyme A reductase genes and antimicrobial isoprenoids in Solanum tuberosum L.
Infections
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Infections
Porcine HMGCR Inhibits Porcine Circovirus Type 2 Infection by Directly Interacting with the Viral Proteins.
Infections
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Infections
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Infections
Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis.
Infections
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.
Infections
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Infertility, Male
Loss of function of 3-hydroxy-3-methylglutaryl coenzyme A reductase 1 (HMG1) in Arabidopsis leads to dwarfing, early senescence and male sterility, and reduced sterol levels.
Inflammatory Bowel Diseases
Hypothalamic digoxin, hemispheric chemical dominance, and inflammatory bowel disease.
Influenza, Human
Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.
Insulin Resistance
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Insulin Resistance
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Insulin Resistance
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Insulin Resistance
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Insulin Resistance
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Insulin Resistance
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Insulin Resistance
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Insulin Resistance
Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
Insulin Resistance
High-Efficacy ?,?-Dehydromonacolin S Improves Hepatic Steatosis and Suppresses Gluconeogenesis Pathway in High-Fat Diet-Induced Obese Rats.
Insulin Resistance
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
Insulin Resistance
Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
Insulin Resistance
Rauwolfia serpentina improves altered glucose and lipid homeostasis in fructose-induced type 2 diabetic mice.
Insulin Resistance
The Effect of HMG-CoA Reductase Inhibitor on Insulin Resistance in Patients Undergoing Peritoneal Dialysis.
Insulin Resistance
The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.
Insulin Resistance
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Insulin Resistance
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.
Intermittent Claudication
Peripheral arterial disease: a review of disease awareness and management.
Intracranial Hemorrhages
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Iron Overload
Iron overload potentiates diet-induced hypercholesterolemia and reduces liver PPAR-? expression in hamsters.
Irritable Bowel Syndrome
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Ischemic Attack, Transient
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Ischemic Attack, Transient
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Ischemic Stroke
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
Ischemic Stroke
HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
Ischemic Stroke
HMG-CoA reductase inhibitors improve acute ischemic stroke outcome.
Ischemic Stroke
Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality.
Ischemic Stroke
Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition.
Ischemic Stroke
Prevention of stroke and dementia with statins: Effects beyond lipid lowering.
Ischemic Stroke
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Ischemic Stroke
Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke.
Ischemic Stroke
The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.
Kidney Diseases
Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats.
Kidney Diseases
Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease.
Kidney Diseases
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Kidney Failure, Chronic
Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.
Kidney Failure, Chronic
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Kidney Failure, Chronic
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Kidney Failure, Chronic
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Kidney Failure, Chronic
Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
Kidney Failure, Chronic
HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
Kidney Failure, Chronic
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.
Kidney Neoplasms
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Kidney Neoplasms
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Leber Congenital Amaurosis
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Leprosy
Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients--a further probe into cholesterol metabolism.
Leukemia
Calcium ionophore treatment impairs the sterol-mediated suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coenzyme A synthase, and farnesyl diphosphate synthetase.
Leukemia
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
Leukemia
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Leukemia
Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells.
Leukemia
Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.
Leukemia
P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Leukemia
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Leukemia
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
Leukemia
[Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1].
Leukemia, Erythroblastic, Acute
Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors.
Leukemia, Hairy Cell
Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells.
Leukemia, Monocytic, Acute
[Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1].
Leukemia, Myeloid, Acute
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Leukemia, Myeloid, Acute
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Leukemia, Myeloid, Acute
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.
Leukemia, Myeloid, Acute
Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours.
Leukostasis
CD11b+ bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation.
Lipidoses
Effect of pravastatin, a HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed White Carneau pigeons.
Lipidoses
Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine.
Lipodystrophy
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study.
Lipomatosis
Molecular biology of metabolic disease: defects in the regulation of enzymic activity.
Liver Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Liver Diseases
Effects of sepsis on the metabolism of sphingomyelin and cholesterol in mice with liver dysfunction.
Liver Diseases
Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Liver Diseases
Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease : A Retrospective Cohort Study.
Liver Diseases
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Liver Diseases
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Liver Diseases
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Liver Diseases
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
Liver Diseases
[Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
Liver Neoplasms
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Liver Neoplasms, Experimental
Effect of assay temperature on the kinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatoma 5123C.
Liver Neoplasms, Experimental
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Lung Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Lung Diseases
Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
Lung Diseases
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Lung Diseases, Interstitial
Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.
Lung Diseases, Interstitial
Statins and Pulmonary Fibrosis: The Potential Role of NLRP3 Inflammasome Activation.
Lung Neoplasms
In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent.
Lung Neoplasms
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Lung Neoplasms
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Lupus Erythematosus, Systemic
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Lupus Erythematosus, Systemic
Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
Lymphatic Metastasis
Clinical relevance of cholesterol homeostasis genes in colorectal cancer.
Lymphoma
Anti-HMGCR Antibody-Positive Myopathy Shows Bcl-2-Positive Inflammation and Lymphocytic Accumulations.
Lymphoma
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Lymphoma
Autophagy contributes to apoptosis in A20 and EL4 lymphoma cells treated with fluvastatin.
Lymphoma
HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.
Lymphoma
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Lymphoma
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Lymphoma
Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Lymphoma, B-Cell
Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease.
Lymphoma, Non-Hodgkin
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.
Lymphoma, Non-Hodgkin
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Macular Degeneration
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study.
Macular Degeneration
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Marek Disease
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Medulloblastoma
Cell-cycle gene expression in lovastatin-induced medulloblastoma apoptosis.
Medulloblastoma
Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines.
Melanoma
Biphenylalkylacetylhydroquinone ethers suppress the proliferation of murine B16 melanoma cells.
Melanoma
Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.
Melanoma
Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
Melanoma
Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.
Melanoma
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Melanoma, Experimental
d-?-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.
Melanoma, Experimental
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Meningioma
Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
Metabolic Diseases
Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis.
Metabolic Diseases
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
Metabolic Syndrome
A Mediterranean-style, low-glycemic-load diet reduces the expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in mononuclear cells and plasma insulin in women with metabolic syndrome.
Metabolic Syndrome
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Metabolic Syndrome
Correction to: HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Metabolic Syndrome
Corrigendum to: HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Metabolic Syndrome
Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome.
Metabolic Syndrome
Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
Metabolic Syndrome
HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Metabolic Syndrome
Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives.
Metabolic Syndrome
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Metabolic Syndrome
Prevention of cardiovascular complications of the metabolic syndrome: focus on pharmacotherapy.
Metabolic Syndrome
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
Metabolic Syndrome
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Mevalonate Kinase Deficiency
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured fibroblasts from patients with mevalonate kinase deficiency: differential response to lipid supplied by fetal bovine serum in tissue culture medium.
Mevalonate Kinase Deficiency
Clinical and biochemical phenotype in 11 patients with mevalonic aciduria.
Microvascular Angina
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.
Mitochondrial Myopathies
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin.
Mucocutaneous Lymph Node Syndrome
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Multiple Myeloma
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Multiple Myeloma
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
Multiple Myeloma
[In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266]
Multiple Sclerosis
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Multiple Sclerosis
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Multiple Sclerosis
HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis.
Multiple Sclerosis
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Multiple Sclerosis
Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy.
Multiple Sclerosis
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Multiple Sclerosis
The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?
Multiple Sclerosis, Chronic Progressive
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Multiple Sclerosis, Relapsing-Remitting
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Muscle Weakness
Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report.
Muscle Weakness
Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.
Muscular Atrophy
Coenzyme Q10 protects against statin-induced myotoxicity in zebrafish larvae (Danio rerio).
Muscular Diseases
Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report.
Muscular Diseases
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study.
Muscular Diseases
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Muscular Diseases
Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy.
Muscular Diseases
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy.
Muscular Diseases
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.
Muscular Diseases
Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.
Muscular Diseases
Case Report: Immune Mediated Necrotizing Myopathy With IgG Antibodies to 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase (HMGCR) May Present With Acute Systolic Heart Failure.
Muscular Diseases
Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Muscular Diseases
Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.
Muscular Diseases
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Muscular Diseases
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Muscular Diseases
Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats.
Muscular Diseases
Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Muscular Diseases
Effect of simvastatin on passive strain-induced skeletal muscle injury in rats.
Muscular Diseases
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Muscular Diseases
Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study.
Muscular Diseases
Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method.
Muscular Diseases
Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Muscular Diseases
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Muscular Diseases
Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
Muscular Diseases
High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults.
Muscular Diseases
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Muscular Diseases
HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients.
Muscular Diseases
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Muscular Diseases
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
Muscular Diseases
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
Muscular Diseases
Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts.
Muscular Diseases
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Muscular Diseases
Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts.
Muscular Diseases
Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine.
Muscular Diseases
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Muscular Diseases
Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle.
Muscular Diseases
Mechanism underlying long-term regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase during L6 myoblast differentiation.
Muscular Diseases
Mining directional drug interaction effects on myopathy using the FAERS database.
Muscular Diseases
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Muscular Diseases
Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature.
Muscular Diseases
Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report.
Muscular Diseases
Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.
Muscular Diseases
Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies.
Muscular Diseases
Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.
Muscular Diseases
Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.
Muscular Diseases
Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies.
Muscular Diseases
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Muscular Diseases
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
Muscular Diseases
Rhabdomyolysis after midazolam administration in a cirrhotic patient treated with atorvastatin.
Muscular Diseases
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Muscular Diseases
Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
Muscular Diseases
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
Muscular Diseases
Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.
Muscular Diseases
Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure.
Muscular Diseases
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Muscular Diseases
Spontaneous symptomatic improvement in a pediatric patient with anti-3-hydroxy-3-methylglutraryl-coenzyme A reductase myopathy.
Muscular Diseases
Statin Coadministration Increases the Risk of Daptomycin-Associated Myopathy.
Muscular Diseases
Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?
Muscular Diseases
Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: A review.
Muscular Diseases
Statin-associated autoimmune myopathy: A distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories.
Muscular Diseases
Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: an observational study in Japan.
Muscular Diseases
The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors.
Muscular Diseases
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
Muscular Diseases
Toxicity of a novel HMG-CoA reductase inhibitor in the common marmoset (Callithrix jacchus).
Muscular Diseases
Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.
Muscular Diseases
Which nonautoimmune myopathies are most frequently misdiagnosed as myositis?
Muscular Diseases
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Muscular Diseases
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]
Muscular Diseases
[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies].
Muscular Diseases
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective].
Muscular Diseases
[Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
Muscular Diseases
[Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase]
Muscular Diseases
[Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase]
Muscular Dystrophies
Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report.
Myalgia
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Myalgia
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Myalgia
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Myalgia
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Myalgia
Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.
Mycoses
Induction mechanism of 3-hydroxy-3-methylglutaryl-CoA reductase in potato tuber and sweet potato root tissues.
Myocardial Infarction
A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
Myocardial Infarction
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Myocardial Infarction
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Myocardial Infarction
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Myocardial Infarction
Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction.
Myocardial Infarction
Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use.
Myocardial Infarction
Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.
Myocardial Infarction
Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice.
Myocardial Infarction
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
Myocardial Infarction
Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.
Myocardial Infarction
Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction.
Myocardial Infarction
Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
Myocardial Infarction
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Myocardial Infarction
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Myocardial Infarction
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Myocardial Infarction
HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction.
Myocardial Infarction
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
Myocardial Infarction
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction.
Myocardial Infarction
Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
Myocardial Infarction
Lipid-lowering for prevention of coronary heart disease: what policy now?
Myocardial Infarction
Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Myocardial Infarction
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Myocardial Infarction
Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarction.
Myocardial Infarction
Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
Myocardial Infarction
Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats.
Myocardial Infarction
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Myocardial Infarction
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Myocardial Infarction
Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
Myocardial Infarction
Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat.
Myocardial Infarction
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
Myocardial Infarction
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
Myocardial Infarction
The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice.
Myocardial Infarction
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Myocardial Infarction
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Myocardial Infarction
Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI.
Myocardial Infarction
[Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]
Myocardial Ischemia
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Myocardial Ischemia
Can simvastatin promote tumor growth by inducing angiogenesis similar to VEGF?
Myocardial Ischemia
Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals.
Myocardial Ischemia
HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
Myocardial Ischemia
Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases.
Myocardial Ischemia
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Myocardial Ischemia
Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins.
Myocardial Ischemia
Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.
Myocardial Ischemia
The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease.
Myocardial Stunning
Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs.
Myocardial Stunning
Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Myocarditis
HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation.
Myositis
Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies.
Myositis
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients.
Myositis
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Myositis
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Myositis
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Myositis
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Myositis
Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies.
Myositis
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Myositis
Spontaneous symptomatic improvement in a pediatric patient with anti-3-hydroxy-3-methylglutraryl-coenzyme A reductase myopathy.
Myositis
Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.
Myositis
Weakness Due to Anemia? Go Fish! Melena as a Red Herring in the Diagnosis of Statin-Induced Myopathy.
Myositis
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Myotonia
HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway.
Myotoxicity
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.
Myotoxicity
Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells.
Myotoxicity
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Myotoxicity
Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions.
Myotoxicity
HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
Myotoxicity
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
Myotoxicity
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Myotoxicity
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Myotoxicity
Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature.
Myotoxicity
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Myotoxicity
Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Myotoxicity
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Myotoxicity
The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.
Neoplasm Metastasis
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Neoplasm Metastasis
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Neoplasm Metastasis
Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice.
Neoplasm Metastasis
Clinical relevance of cholesterol homeostasis genes in colorectal cancer.
Neoplasm Metastasis
Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.
Neoplasm Metastasis
Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
Neoplasm Metastasis
Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-?-treated epithelial cancer cells.
Neoplasm Metastasis
Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Neoplasm Metastasis
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Neoplasm Metastasis
HMGCR positively regulated the growth and migration of glioblastoma cells.
Neoplasm Metastasis
MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Neoplasm Metastasis
Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors.
Neoplasm Metastasis
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Neoplasm Metastasis
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Neoplasms
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.
Neoplasms
3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
Neoplasms
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest.
Neoplasms
3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.
Neoplasms
6-Nitrocholesterol inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase and tumor cell growth.
Neoplasms
A bovine oviduct epithelial cell suspension culture system suitable for studying embryo-maternal interactions: morphological and functional characterization.
Neoplasms
A discoordinate increase in the cellular amount of 3-hydroxy-3-methylglutaryl-CoA reductase results in the loss of rate-limiting control over cholesterogenesis in a tumour cell-free system.
Neoplasms
A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer.
Neoplasms
A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.
Neoplasms
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
Neoplasms
A single nucleotide polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene ( HMGCR) influences the serum triacylglycerol relationship with dietary fat and fibre in the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study.
Neoplasms
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
Neoplasms
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Neoplasms
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Neoplasms
Adiponectin Attenuates the Inflammation in Atopic Dermatitis-Like Reconstructed Human Epidermis.
Neoplasms
Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase(®).
Neoplasms
Alterations in biosynthesis and homeostasis of cholesterol and in lipoprotein patterns in mice bearing a transplanted lymphoid tumor.
Neoplasms
Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors.
Neoplasms
Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines.
Neoplasms
Anti-proliferative activity of Origanum vulgare inhibited lipogenesis and induced mitochondrial mediated apoptosis in human stomach cancer cell lines.
Neoplasms
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Neoplasms
Antihyperlipidemic effect of selected pyrimidine derivatives mediated through multiple pathways.
Neoplasms
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Neoplasms
Association between serum concentrations of perfluoroalkyl substances (PFAS) and expression of serum microRNAs in a cohort highly exposed to PFAS from drinking water.
Neoplasms
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Neoplasms
Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype.
Neoplasms
Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway.
Neoplasms
Autoimmune-like drug-induced liver injury: a review and update for the clinician.
Neoplasms
Blocking late cholesterol biosynthesis inhibits the growth of transplanted Morris hepatomas (7288CTC) in rats.
Neoplasms
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Neoplasms
Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.
Neoplasms
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Neoplasms
Cholesterol Biosynthesis and Trafficking in Cortisol-Producing Lesions of the Adrenal Cortex.
Neoplasms
Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response.
Neoplasms
Cholesterol metabolism in human cancer cells in monolayer culture. V. The effect of progesterone on the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by low density lipoprotein.
Neoplasms
Comparison of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma cells grown in vivo and in vitro.
Neoplasms
Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
Neoplasms
Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-?-treated epithelial cancer cells.
Neoplasms
CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-? signaling.
Neoplasms
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Neoplasms
d-Dlta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells.
Neoplasms
Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Neoplasms
Dietary alpha-tocopherol attenuates the impact of gamma-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens.
Neoplasms
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
Neoplasms
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Neoplasms
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Neoplasms
Differentiation and apoptosis induction by lovastatin and ?-tocotrienol in HL-60 cells via Ras/ERK/NF-?B and Ras/Akt/NF-?B signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase.
Neoplasms
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
Neoplasms
Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth.
Neoplasms
Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo.
Neoplasms
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Neoplasms
Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway.
Neoplasms
EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers.
Neoplasms
Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells: Potential Mechanisms Contributing to Progression of HER2-Positive Breast Cancers.
Neoplasms
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL.
Neoplasms
Enhancement of sterol synthesis by the monoterpene perillyl alcohol is unaffected by competitive 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.
Neoplasms
Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions.
Neoplasms
Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas.
Neoplasms
Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells.
Neoplasms
Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin.
Neoplasms
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Neoplasms
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Neoplasms
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
Neoplasms
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Neoplasms
HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation.
Neoplasms
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
Neoplasms
HMGCoA reductase inhibition partially mediates tumor necrosis factor alpha-induced apoptosis in human U-937 and HL-60 cells.
Neoplasms
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
Neoplasms
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Neoplasms
Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.
Neoplasms
Identification of developmental competence-related genes in mature porcine oocytes.
Neoplasms
Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study.
Neoplasms
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
Neoplasms
In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.
Neoplasms
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Neoplasms
Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin.
Neoplasms
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Neoplasms
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Neoplasms
Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.
Neoplasms
Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Neoplasms
Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Neoplasms
Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations.
Neoplasms
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Neoplasms
Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma.
Neoplasms
Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation.
Neoplasms
Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer.
Neoplasms
Kinetics of G1 progression in 3T6 and SV-3T3 cells following treatment by 25-hydroxycholesterol.
Neoplasms
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Neoplasms
Lipid metabolism in cultured cells. XVI. Lipoprotein binding and HMG CoA reductase levels in normal and tumor virus-transformed human fibroblasts.
Neoplasms
Lipophilic but not hydrophilic statins selectively induce cell death in gynecological cancers expressing high levels of HMGCoA reductase.
Neoplasms
Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling.
Neoplasms
Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal.
Neoplasms
Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation--impact of Ras-/Rho-prenylation.
Neoplasms
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.
Neoplasms
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Neoplasms
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells.
Neoplasms
Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP.
Neoplasms
Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.
Neoplasms
Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement.
Neoplasms
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Neoplasms
Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines.
Neoplasms
Metabolome of Mammary Tumors Differs from Normal Mammary Glands But Is Not Altered by Time-restricted Feeding Under Obesogenic Conditions.
Neoplasms
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.
Neoplasms
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
Neoplasms
Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).
Neoplasms
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase.
Neoplasms
Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report.
Neoplasms
Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
Neoplasms
Organ- and tissue-specific expression of the low density lipoprotein receptor. Rapid quantitation by competitive reverse transcriptasepolymerase chain reaction.
Neoplasms
Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells.
Neoplasms
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Neoplasms
Posttranscriptional regulation of mRNA levels in rat liver associated with deoxycholic acid feeding.
Neoplasms
Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank.
Neoplasms
Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Neoplasms
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Neoplasms
Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.
Neoplasms
Proteomics and bioinformatics analysis of lovastatin-induced differentiation in ARO cells.
Neoplasms
Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis.
Neoplasms
Rapid quantitation of mRNA species in ethidium bromide-stained gels of competitive RT-PCR products.
Neoplasms
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Neoplasms
Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells.
Neoplasms
Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.
Neoplasms
Simvastatin effects on a human lung carcinoma and cholesterol homeostasis of host and non-host mice.
Neoplasms
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Neoplasms
Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells.
Neoplasms
Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and ?-Catenin Signaling.
Neoplasms
Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells.
Neoplasms
Simvastatin suppresses breast cancer cell proliferation induced by senescent cells.
Neoplasms
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Neoplasms
Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
Neoplasms
Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
Neoplasms
Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Neoplasms
Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma.
Neoplasms
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Neoplasms
Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women.
Neoplasms
Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation.
Neoplasms
Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells.
Neoplasms
Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.
Neoplasms
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).
Neoplasms
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Neoplasms
Suppression in Mevalonate Synthesis Mediates Antitumor Effects of Combined Statin and gamma-Tocotrienol Treatment.
Neoplasms
Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
Neoplasms
Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Neoplasms
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Neoplasms
Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.
Neoplasms
Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Neoplasms
Targeting Fatty Acid Synthase Modulates Metabolic Pathways and Inhibits Cholangiocarcinoma Cell Progression.
Neoplasms
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Neoplasms
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Neoplasms
Taxifolin binds with LXR (? & ?) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway.
Neoplasms
The effect of factors released from the tumor-transformed cells on DNA synthesis, mitosis, and cellular enlargement in 3T3 fibroblasts.
Neoplasms
The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia.
Neoplasms
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Neoplasms
The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.
Neoplasms
The potential hepatoprotective effects of lovastatin combined with oral hypoglycemic agents in streptozotocin-induced diabetes in rats.
Neoplasms
The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Neoplasms
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Neoplasms
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective.
Neoplasms
Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
Neoplasms
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Neoplasms
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Neoplasms
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Neoplasms
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer.
Neoplasms
Warburg's Ghost-Cancer's Self-Sustaining Phenotype: The Aberrant Carbon Flux in Cholesterol-Enriched Tumor Mitochondria via Deregulated Cholesterogenesis.
Neoplasms
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
Neoplasms
[The cytotoxicity of mevalonate, lovastatin and carminomycin with respect to MOLT-4 human malignant T-lymphoblasts in vitro]
Nephritis
HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-Thy-1.1 nephritis.
Nephrosclerosis
A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.
Nephrosis
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Nephrosis
Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
Nephrosis
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
Nephrotic Syndrome
Effect of Genistein and L-Carnitine and Their Combination on Gene Expression of Hepatocyte HMG-COA Reductase and LDL Receptor in Experimental Nephrotic Syndrome.
Nephrotic Syndrome
Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
Nephrotic Syndrome
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Nephrotic Syndrome
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Nephrotic Syndrome
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Nephrotic Syndrome
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Nephrotic Syndrome
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Nephrotic Syndrome
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]
Nephrotic Syndrome
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]
Nervous System Diseases
Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome.
Nervous System Diseases
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date.
Neural Tube Defects
HMG-CoA reductase mRNA in the post-implantation rat embryo studied by in situ hybridization.
Neuritis
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Neuritis, Autoimmune, Experimental
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Neuroblastoma
24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury.
Neuroblastoma
Characterization of the response of growth and differentiation to lipoproteins and agents affecting cholesterol metabolism in murine neuroblastoma cells.
Neuroblastoma
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Neuroblastoma
HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells.
Neuroblastoma
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Neuroblastoma
Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Neuroblastoma
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.
Neuroblastoma
RNA-binding protein hnRNPR reduces neuronal cholesterol levels by binding to and suppressing HMGCR.
Neuroblastoma
Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Neuroblastoma
Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor.
Neurodegenerative Diseases
Mevastatin promotes neuronal survival against A?-induced neurotoxicity through AMPK activation.
Neurodegenerative Diseases
Statins and neuroprotection: a prescription to move the field forward.
Neuroectodermal Tumors, Primitive
Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint.
Neurofibromatoses
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
Neurofibromatosis 1
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
Neuroinflammatory Diseases
Rosuvastatin Attenuates High-Salt and Cholesterol Diet Induced Neuroinflammation and Cognitive Impairment via Preventing Nuclear Factor KappaB Pathway.
Neurologic Manifestations
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Neuromuscular Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Nevus, Pigmented
Cholesterol was identified as a biomarker in human melanocytic nevi using DESI and DESI/PI mass spectrometry imaging.
Niemann-Pick Diseases
Type C Niemann-Pick disease fibroblasts and their transformed cell lines are hypersensitive to HMG-CoA reductase inhibitors.
Non-alcoholic Fatty Liver Disease
Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver.
Non-alcoholic Fatty Liver Disease
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Integrated analysis of hepatic mRNA and miRNA profiles identified molecular networks and potential biomarkers of NAFLD.
Non-alcoholic Fatty Liver Disease
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Non-alcoholic Fatty Liver Disease
Meta-analysis reveals up-regulation of cholesterol processes in non-alcoholic and down-regulation in alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Non-alcoholic Fatty Liver Disease
Regulation effects of total flavonoids in Morus alba L. on hepatic cholesterol disorders in orotic acid induced NAFLD rats.
Non-alcoholic Fatty Liver Disease
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
Non-alcoholic Fatty Liver Disease
The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPK?.
Non-alcoholic Fatty Liver Disease
[Effect of leech on lipid metabolism and liver in hyperlipidemia rats].
Non-ST Elevated Myocardial Infarction
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Obesity
African walnut (Tetracarpidium conophorum) modulates hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase.
Obesity
Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells.
Obesity
Evaluation of lipid and cholesterol-lowering effect of bioflavonoids from bergamot extract.
Obesity
Genetic Contribution of Variants near SORT1 and APOE on LDL Cholesterol Independent of Obesity in Children.
Obesity
Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Obesity
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
Obesity
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Obesity
Methanolic Extract of Piper sarmentosum Attenuates Obesity and Hyperlipidemia in Fructose-Induced Metabolic Syndrome Rats.
Obesity
Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
Obesity
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Obesity
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a ?-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
Obesity
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
Obesity
What model organisms and interactomics can reveal about the genetics of human obesity.
Obesity, Abdominal
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Obesity, Abdominal
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Obesity, Abdominal
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]
Optic Nerve Injuries
Sirtuin 1 regulates lipid metabolism associated with optic nerve regeneration.
Osteoarthritis
Atorvastatin inhibited TNF-? induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-?B signaling.
Osteoarthritis
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Osteoarthritis
Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation.
Osteoarthritis, Hip
Association of statin use and development and progression of hip osteoarthritis in elderly women.
Osteolysis
Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis.
Osteoporosis
?-Tocotrienol protects against ovariectomy-induced bone loss via mevalonate pathway as HMG-CoA reductase inhibitor.
Osteoporosis
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Osteoporosis
Comparison of the effects of D-003, a mixture of high-molecular-weight aliphatic acids from sugarcane wax, and pravastatin on bones and osteoclast apoptosis of ovariectomized rats.
Osteoporosis
Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research.
Osteoporosis
HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?
Osteoporosis
Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.
Osteoporosis
No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria.
Osteoporosis
The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits.
Osteoporosis
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Osteoporosis
The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
Osteoporosis
[Inhibitors of HMG-CoA reductase in prevention of osteoporosis and bone fractures. Similar mechanism of action of statins and bisphosphonates]
Osteosarcoma
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion.
Osteosarcoma
Cyr61 downregulation reduces osteosarcoma cell invasion, migration and metastases.
Osteosarcoma
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Ovarian Neoplasms
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Ovarian Neoplasms
Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer - a new pool of biomarkers.
Ovarian Neoplasms
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Ovarian Neoplasms
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Ovarian Neoplasms
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Pancreatic Neoplasms
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Pancreatic Neoplasms
d-Dlta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells.
Pancreatic Neoplasms
Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Pancreatic Neoplasms
Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Pancreatic Neoplasms
Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative.
Pancreatic Neoplasms
Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies.
Pancreatic Neoplasms
YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Pancreatic Neoplasms
[Antiproliferating effect of HMG-CoA reductase inhibitor on human pancreatic cancer cell]
Pancreatitis
Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports.
Paralysis
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Parkinson Disease
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Parkinson Disease
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Parkinson Disease
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Parkinson Disease
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Parkinson Disease
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Parkinson Disease
Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.
Parkinson Disease
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Parkinson Disease
Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress.
Parkinsonian Disorders
A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in LRRK2-G2019S parkinsonism.
Pericarditis
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
Peripheral Arterial Disease
The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.
Peripheral Arterial Disease
The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
Peripheral Nervous System Diseases
HMG-CoA reductase inhibitor therapy and peripheral neuropathy.
Peripheral Nervous System Diseases
Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Peripheral Vascular Diseases
Peripheral arterial disease: a review of disease awareness and management.
Peripheral Vascular Diseases
Recrudescence of Old Stroke Deficits Among Transient Neurological Attacks.
Phenylketonurias
Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis.
Pinguecula
Hyperexpression of low-density lipoprotein receptors and hydroxy-methylglutaryl-coenzyme A-reductase in human pinguecula and primary pterygium.
Pityriasis Lichenoides
Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
Polycystic Kidney Diseases
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Polycystic Kidney Diseases
Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.
Polycystic Ovary Syndrome
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.
Polymyositis
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Polymyositis
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Polymyositis
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective].
Porphyria Cutanea Tarda
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]
Porphyrias
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]
Prediabetic State
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Preleukemia
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Prostatic Neoplasms
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Prostatic Neoplasms
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
Prostatic Neoplasms
Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE.
Prostatic Neoplasms
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Prostatic Neoplasms
Citral Induced Apoptosis through Modulation of Key Genes Involved in Fatty Acid Biosynthesis in Human Prostate Cancer Cells: In Silico and In Vitro Study.
Prostatic Neoplasms
Correction to: "Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment".
Prostatic Neoplasms
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Prostatic Neoplasms
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
Prostatic Neoplasms
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
Prostatic Neoplasms
Improved Biochemical Outcomes with Statin Use in Patients with High-Risk Localized Prostate Cancer Treated with Radiotherapy.
Prostatic Neoplasms
Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Prostatic Neoplasms
Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
Prostatic Neoplasms
MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells.
Prostatic Neoplasms
Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature (February).
Prostatic Neoplasms
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer.
Prostatic Neoplasms
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Prostatic Neoplasms
Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR.
Prostatic Neoplasms
The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.
Prostatic Neoplasms
Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
Proteinuria
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.
Proteinuria
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
Proteinuria
Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Proteinuria
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Proteinuria
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Pterygium
Hyperexpression of low-density lipoprotein receptors and hydroxy-methylglutaryl-coenzyme A-reductase in human pinguecula and primary pterygium.
Pulmonary Arterial Hypertension
Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway.
Pulmonary Aspergillosis
Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1.
Pulmonary Disease, Chronic Obstructive
Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study.
Pulmonary Disease, Chronic Obstructive
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Rectal Neoplasms
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Renal Insufficiency
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
Renal Insufficiency
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Renal Insufficiency
Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.
Renal Insufficiency
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Renal Insufficiency
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Renal Insufficiency
Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative : A Critical Review of Potential Benefits and Drawbacks.
Renal Insufficiency
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Renal Insufficiency
HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.
Renal Insufficiency
Lipids, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, and progression of renal failure.
Renal Insufficiency
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Renal Insufficiency
Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7 alpha-hydroxylase in rats with subtotal nephrectomy.
Renal Insufficiency
Protective Effects of Rosuvastatin in Experimental Renal Failure Rats via Improved Endothelial Function.
Renal Insufficiency
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
Renal Insufficiency
Statins and renal diseases: from primary prevention to renal replacement therapy.
Renal Insufficiency
The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
Renal Insufficiency, Chronic
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway.
Renal Insufficiency, Chronic
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Renal Insufficiency, Chronic
Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Renal Insufficiency, Chronic
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
Renal Insufficiency, Chronic
Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.
Renal Insufficiency, Chronic
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
Renal Insufficiency, Chronic
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Renal Insufficiency, Chronic
Low utilization of secondary preventive medications and its potential impact in patients with chronic kidney disease and acute coronary syndromes.
Renal Insufficiency, Chronic
Nephroprotective and clinical potential of statins in dialyzed patients.
Renal Insufficiency, Chronic
Optimal Medical Management in Patients with Renovascular Hypertension.
Renal Insufficiency, Chronic
The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients.
Renal Insufficiency, Chronic
Therapeutic considerations for the use of statin therapy in chronic renal disease.
Renal Insufficiency, Chronic
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Renal Insufficiency, Chronic
[Statins in patients with renal failure--the current therapeutic status]
Reperfusion Injury
HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury.
Reperfusion Injury
Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury.
Reperfusion Injury
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels.
Reperfusion Injury
The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury.
Retinal Diseases
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction.
Retinal Neovascularization
HMG-CoA reductase inhibitors (statins) prevents retinal neovascularization in a model of oxygen-induced retinopathy.
Retinoblastoma
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).
Reye Syndrome
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Rhabdomyolysis
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
Rhabdomyolysis
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Rhabdomyolysis
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Rhabdomyolysis
Case of the month: February 1999--54 year old man with severe muscle weakness.
Rhabdomyolysis
Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Rhabdomyolysis
Currently available hypolipidaemic drugs and future therapeutic developments.
Rhabdomyolysis
Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?
Rhabdomyolysis
Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors.
Rhabdomyolysis
Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction.
Rhabdomyolysis
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Rhabdomyolysis
Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions.
Rhabdomyolysis
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Rhabdomyolysis
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Rhabdomyolysis
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Rhabdomyolysis
Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
Rhabdomyolysis
HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
Rhabdomyolysis
HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway.
Rhabdomyolysis
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Rhabdomyolysis
Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Rhabdomyolysis
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Rhabdomyolysis
Levofloxacin-induced rhabdomyolysis in a patient on concurrent atorvastatin: Case report and literature review.
Rhabdomyolysis
Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors.
Rhabdomyolysis
Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme: A reductase inhibitor-induced rhabdomyolysis.
Rhabdomyolysis
Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.
Rhabdomyolysis
Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole.
Rhabdomyolysis
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Rhabdomyolysis
Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Rhabdomyolysis
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Rhabdomyolysis
Red mold dioscorea: a potentially safe traditional function food for the treatment of hyperlipidemia.
Rhabdomyolysis
Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Rhabdomyolysis
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Rhabdomyolysis
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.
Rhabdomyolysis
Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.
Rhabdomyolysis
Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Rhabdomyolysis
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Rhabdomyolysis
Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.
Rhabdomyolysis
Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Rhabdomyolysis
Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan?.
Rhabdomyolysis
Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.
Rhabdomyolysis
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Rhabdomyolysis
Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient.
Rhabdomyolysis
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Rhabdomyolysis
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.
Rhabdomyolysis
Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Rhabdomyolysis
[Neurological complication due to the drug and the maneuver for the treatment and prevention of cerebrovascular diseases: iatrogenic neurology]
Rhabdomyolysis
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
Rhabdomyolysis
[Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and chlorzoxazone]
Rhabdomyolysis
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Rheumatic Diseases
An integrative biology approach for analysis of drug action in models of human vascular inflammation.
Rheumatic Diseases
An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.
Rosacea
The Risk of Rosacea According to Chronic Diseases and Medications: A 5-Year Retrospective, Multi-Institutional Case-Control Study.
Sarcoidosis
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Sarcoma
Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
Sarcoma, Ewing
Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Sarcoma, Ewing
Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint.
Scarlet Fever
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women.
Seizures
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Seizures
Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice.
Sepsis
Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for Gram-Negative rods.
Sepsis
Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation.
Sepsis
Effects of sepsis on the metabolism of sphingomyelin and cholesterol in mice with liver dysfunction.
Sepsis
HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.
Sepsis
Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis.
Sepsis
Incidence of Sepsis and Mortality With Prior Exposure of HMG-COA Reductase Inhibitors in a Surgical Intensive Care Population.
Sepsis
Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
Sepsis
Reduction in mortality associated with statin therapy in patients with severe sepsis.
Sepsis
Renal cortical cholesterol accumulation is an integral component of the systemic stress response.
Sepsis
Sepsis outcomes in patients receiving statins prior to hospitalization for sepsis: comparison of in-hospital mortality rates between patients who received atorvastatin and those who received simvastatin.
Sepsis
Sepsis syndrome stimulates proximal tubule cholesterol synthesis and suppresses the SR-B1 cholesterol transporter.
Shock, Septic
Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
Shock, Septic
Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats.
Sleep Initiation and Maintenance Disorders
Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects.
Smith-Lemli-Opitz Syndrome
Plasma and thrombocyte levels of coenzyme Q10 in children with Smith-Lemli-Opitz syndrome (SLOS) and the influence of HMG-CoA reductase inhibitors.
Spasm
Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.
Spinal Stenosis
Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis.
Squamous Cell Carcinoma of Head and Neck
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
ST Elevation Myocardial Infarction
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Starvation
Acute effects of starvation and treatment of rats with anti-insulin serum, glucagon and catecholamines on the state of phosphorylation of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase in vivo.
Starvation
Acute effects of starvation and treatment of rats with anti-insulin serum, glucagon and catecholamines on the state of phosphorylation of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase.
Starvation
Kinetics of G1 progression in 3T6 and SV-3T3 cells following treatment by 25-hydroxycholesterol.
Starvation
Serum cholesterol, lecithin-cholesterol acyltransferase, and hepatic hydroxymethylglutaryl coenzyme A reductase activities of lean and obese Zucker rats.
Starvation
[Activities of 3-hydroxyl-3-methylglutaryl-CoA reductase and acetyl-CoA carboxylase and the rate of mevalonic acid, squalene, sterol and fatty acid biosynthesis from [1-14C]acetyl-CoA and [2-14C]malonyl-CoA in rat liver: effects of Triton WR 1339, starvation and cholesterol diet]
Stomach Neoplasms
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer.
Stomach Neoplasms
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Stomach Neoplasms
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Stroke
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy.
Stroke
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Stroke
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
Stroke
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Stroke
Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.
Stroke
Chemokine, vascular and therapeutic effects of combination Simvastatin and BMSC treatment of stroke.
Stroke
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
Stroke
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Stroke
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Stroke
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.
Stroke
HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
Stroke
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Stroke
HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.
Stroke
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.
Stroke
HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention.
Stroke
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Stroke
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis.
Stroke
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
Stroke
Molecular mechanisms underlying the effects of statins in the central nervous system.
Stroke
Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Stroke
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Stroke
Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats.
Stroke
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Stroke
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
Stroke
Statin use before and after acute ischemic stroke onset improves neurological outcome.
Stroke
Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke.
Stroke
Statins Promote Long-Term Recovery after Ischemic Stroke by Reconnecting Noradrenergic Neuronal Circuitry.
Stroke
Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors.
Stroke
The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
Stroke
The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.
Stroke
[Novel actions of HMG-CoA reductase inhibitors(statins)--vascular and cerebral protection through inhibition of small GTPase Rho]
Subacute Sclerosing Panencephalitis
Hypothalamic digoxin-mediated model for subacute sclerosing panencephalitis.
Subarachnoid Hemorrhage
Statin treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Tachycardia, Ventricular
Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
Tendinopathy
The influence of atorvastatin on tendon healing: an experimental study on rabbits.
Thromboinflammation
The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome.
Thrombosis
HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats.
Thrombosis
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
Thrombosis
Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy.
Thrombosis
Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells.
Thrombosis
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Thyroid Carcinoma, Anaplastic
Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.
Thyroid Carcinoma, Anaplastic
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells.
Thyroid Nodule
Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment.
Thyroiditis
The effect of statin therapy on thyroid autoimmunity in patients with Hashimoto's thyroiditis: A pilot study.
Tinnitus
Simvastatin and Ginkgo biloba in the treatment of subacute tinnitus: a retrospective study of 94 patients.
Tourette Syndrome
Hypothalamic digoxin deficiency in obsessive compulsive disorder and la Tourette's syndrome.
Tuberculosis
Effect of HMG-CoA reductase inhibitors on activation of human gammadeltaT cells induced by Mycobacterium tuberculosis antigens.
Tuberculosis
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Tuberous Sclerosis
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Uterine Cervical Neoplasms
Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways.
Varicose Veins
HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins.
Vascular Diseases
Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.
Vascular Diseases
Detection of familial hypercholesterolemia in patients from a general practice database.
Vascular Diseases
Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
Vascular Diseases
Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts.
Vascular Diseases
Statins Promote Long-Term Recovery after Ischemic Stroke by Reconnecting Noradrenergic Neuronal Circuitry.
Vascular Diseases
Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease.
Vascular Diseases
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
Vascular System Injuries
gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism.
Vascular System Injuries
Rosuvastatin reduces neointima formation in a rat model of balloon injury.
Vasospasm, Intracranial
Proposed mechanism of cerebral vasospasm: our hypothesis and current topics.
Venous Thromboembolism
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.
Venous Thromboembolism
Why might statins prevent venous thromboembolism: what needs to be done to know more?
Venous Thrombosis
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.
Venous Thrombosis
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.
Ventricular Dysfunction, Left
Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase.
Viremia
Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia.
Virus Diseases
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Virus Diseases
Effect of atovastatin treatment on porcine circovirus 2 infection in BALB/c mice.
Virus Diseases
HMGCR inhibits the early stage of PCV2 infection, while PKC enhances the infection at the late stage.
Virus Diseases
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Vitamin D Deficiency
Increase of circulating cholesterol in vitamin D deficiency is linked to reduced vitamin D receptor activity via the Insig-2/SREBP-2 pathway.
Xanthomatosis
Decreased cholesterol biosynthesis in sitosterolemia with xanthomatosis: diminished mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and enzyme protein associated with increased low-density lipoprotein receptor function.
Xanthomatosis
Familial xanthomatous hypercholesterolemia: abnormal exogenous lipid metabolism evidenced by the vitamin A test.
Xanthomatosis
Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols.
Xanthomatosis
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Xanthomatosis
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Xanthomatosis, Cerebrotendinous
Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Xanthomatosis, Cerebrotendinous
Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.6
3-hydroxy-3-methylglutaryl-CoA
-
pH 7.5, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
additional information
additional information
-
steady state inhibition kinetics
-
additional information
additional information
-
inhibition kinetics of different plant extracts, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.201
Ile-Ala-Val-Pro-Gly-Glu-Val-Ala
Homo sapiens
-
pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
NCTC 2544 cells. HMG-CoA reductase and peroxisome proliferator-activated receptor alpha are involved in clofibrate-induced apoptosis in human keratinocytes
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
metabolism
physiological function
additional information
metabolism
HMG-CoA reductase is the rate-limiting enzyme of cholesterol biosynthesis
metabolism
HMGR catalyzes the four-electron reduction of HMGCoA to mevalonate, the committed step in the biosynthesis of sterols. Mevalonate is a precursor of isoprenoids, a class of compounds involved in several cellular functions such as cholesterol synthesis and growth control
metabolism
rate-limiting enzyme in mammalian phosphatidylethanolamine biosynthesis
physiological function
within cells, the concentration of mevalonate and therefore that of its metabolic products is tightly controlled through the activity of HMGR, an enzyme that catalyzes the four-electron reduction of 3-hydroxy-3-methylglutaryl-CoA to mevalonate
physiological function
-
the enzyme is the major regulatory enzyme of cholesterol biosynthesis and the target enzyme of many investigations aimed at lowering the rate of cholesterol biosynthesis
additional information
modelling of the active site using crystal stucture of the enzyme with bound inhibitor simvastatin, PDB ID 1HW9, overview
additional information
devlopment of three molecular models of human enzyme with different active site protonation states, and reaction mechanism analysis by molecular dynamics and quantum mechanics/molecular mechanics (QM/MM) calculations to detail the first reduction step, the rate-limiting step, of HMG-CoA-R
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). HMDH_HUMAN
888
5
97476
Swiss-Prot
Secretory Pathway (Reliability: 4)
H0Y8K6_HUMAN
165
0
17462
TrEMBL
other Location (Reliability: 1)
A0A7P0Z481_HUMAN
873
5
95995
TrEMBL
Secretory Pathway (Reliability: 4)
H0Y8F6_HUMAN
115
0
12307
TrEMBL
other Location (Reliability: 1)
B2R649_HUMAN
888
5
97462
TrEMBL
Secretory Pathway (Reliability: 4)
B4DSB1_HUMAN
265
0
28127
TrEMBL
Secretory Pathway (Reliability: 5)
A8KA27_HUMAN
888
5
97460
TrEMBL
Secretory Pathway (Reliability: 4)
A0A024RAP2_HUMAN
888
5
97476
TrEMBL
Secretory Pathway (Reliability: 4)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
dimer
the catalytic portion of human HMG-CoA, after cleavage of the probable dimeric form found in the endoplasmic reticulum, 18 crystallized as a dimer of dimers. However, the dimer-dimer interface is distant from the active site and only the dimer of the molecule seems crucial for catalysis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
phosphoprotein
proteolytic modification
-
proteolysis releases a soluble, active fragment of 52-56 kDa
additional information
-
genistein, eicosapentaenoic acid and docosahexaenoic acid down-regulate reductase activity, primarily through posttranscriptional effects
phosphoprotein
the enzyme is phosphorylated at Ser872 by AMP-activated protein kinase and reversibly dephosphorylated by phosphatase 2A
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
analysis of the enzyme crystal structure (PDV ID 1DQA) at 2.0 A resolution
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Q766H
-
restores viability of Saccharomyces cerevisiae strains lacking the HMG1 and HMG2 genes, thus is catalytically active in yeast cells. Q766H mutation, which affects the structure of the catalytic domain, increases the sensitivity of the enzyme towards statin treatment
R393Q
-
restores viability of Saccharomyces cerevisiae strains lacking the HMG1 and HMG2 genes, thus is catalytically active in yeast cells. R393Q mutation does not change the properties of the enzyme towards statin treatment
S872D
the mutation reduces the catalytic activity of the enzyme similarly to that of the phosphorylated enzyme
additional information
-
expression of human HMG-CoA reductase in yeast complements the lethal phenotype of Saccharomyces cerevisiae strains lacking the HMG1 and HMG2 genes
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
cDNA encoding the wild-type and mutant forms of human HMG-CoA reductase expressed under control of the yeast MET25 promoter in a Saccharomyces cerevisiae strain with deletions of both HMG1 and HMG2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
increased Hmgcr mRNA levels after serum starvation are suppressed by 25-hydroxycholesterol. The suppressive effect of 25-hydroxycholesterol on mRNA transcription is ameliorated by trichostatin A. Anacardic acid, 25-hydroxycholesterol and 24(S)-hydroxycholesterol suppress the transcription by inhibiting H3K27 acetylation in the promoter. 27-Hydroxycholesterol, 22(S)-hydroxycholesterol and 22(R)-hydroxycholesterol suppress the transcription
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
drug development
-
a yeast expression system can serve to study the influence of selected mutations in human HMG-CoA reductase on the sensitivity of the enzyme to commonly prescribed statins, thus this model system is suitable for the development and selection of lipid-lowering drugs as well as for the examination of DNA sequence variations in the context of statin therapy
medicine
medicine
-
the enzyme is a target for intervention in the treatment of hypercholesterolaemia, clinical utility of inhibitors to decrease the levels of atherogenic lipiproteins in patients
medicine
-
genistein, eicosapentaenoic acid and docosahexaenoic acid down-regulate reductase activity, primarily through posttranscriptional effects. Diets rich in soy isoflavones and fish oils, therefore, may exert anti-cancer effects through the inhibition of mevalonate synthesis in the breast. Genistein and docosahexaenoic acid, in particular, may augment the efficacy of statins, increasing the potential for use of these drugs in adjuvant therapy for breast cancer
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Harwood, Jr., H.J.; Schneider, M.; Stacpool, P.W.
Regulation of human leukocyte microsomal hydroxymethylglutaryl-CoA reductase activity by a phosphorylation and dephosphorylation mechanism
Biochim. Biophys. Acta
805
245-251
1984
Homo sapiens
brenda
Hupperich, M.; Thomer, A.; Kratz, K.; Eggerer, H.
Substrate and inhibitor specificity of 3-hydroxy-3-methylglutaryl-CoA reductase determined with substrate-analogue CoA-thioesters and CoA-thioethers
Biol. Chem. Hoppe-Seyler
372
857-863
1991
Homo sapiens
brenda
Holdgate, G.A.; Ward, W.H.; McTaggart, F.
Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin
Biochem. Soc. Trans.
31
528-531
2003
Homo sapiens
brenda
Garcia-Pelayo, M.C.; Garcia-Peregrin, E.; Martinez-Cayuela, M.
Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells
Exp. Biol. Med.
229
781-786
2004
Homo sapiens
brenda
Muzio, G.; Martinasso, G.; Trombetta, A.; Di Simone, D.; Canuto, R.A.; Maggiora, M.
HMG-CoA reductase and PPARalpha are involved in clofibrate-induced apoptosis in human keratinocytes
Apoptosis
11
265-275
2006
Homo sapiens
brenda
Carbonell, T.; Freire, E.
Binding thermodynamics of statins to HMG-CoA reductase
Biochemistry
44
11741-11748
2005
Homo sapiens (P04035)
brenda
Duncan, R.E.; El-Sohemy, A.; Archer, M.C.
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin
Cancer Lett.
224
221-228
2005
Homo sapiens
brenda
Gueguen, Y.; Ferrari, L.; Souidi, M.; Batt, A.M.; Lutton, C.; Siest, G.; Visvikis, S.
Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase
Basic Clin. Pharmacol. Toxicol.
100
392-397
2007
Homo sapiens
brenda
Subbaiah, P.V.; Sowa, J.M.; Singh, D.K.
Sphingolipids and cellular cholesterol homeostasis. Effect of ceramide on cholesterol trafficking and HMG CoA reductase activity
Arch. Biochem. Biophys.
474
32-38
2008
Homo sapiens
brenda
Seiki, S.; Frishman, W.H.
Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia
Cardiol. Rev.
17
70-76
2009
Homo sapiens
brenda
Wysocka-Kapcinska, M.; Lutyk-Nadolska, J.; Kiliszek, M.; Plochocka, D.; Maciag, M.; Leszczynska, A.; Rytka, J.; Burzynska, B.
Functional expression of human HMG-CoA reductase in Saccharomyces cerevisiae: a system to analyse normal and mutated versions of the enzyme in the context of statin treatment
J. Appl. Microbiol.
106
895-902
2009
Homo sapiens
brenda
Perchellet, J.P.; Perchellet, E.M.; Crow, K.R.; Buszek, K.R.; Brown, N.; Ellappan, S.; Gao, G.; Luo, D.; Minatoya, M.; Lushington, G.H.
Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins
Int. J. Mol. Med.
24
633-643
2009
Homo sapiens (P04035), Homo sapiens
brenda
Gholamhoseinian, A.; Shahouzehi, B.; Sharifi-Far, F.
Inhibitory activity of some plant methanol extracts on 3-hydroxy-3-methylglutaryl coenzyme A reductase
Int. J. Pharmacol.
6
705-711
2010
Homo sapiens
-
brenda
Leopoldini, M.; Malaj, N.; Toscano, M.; Sindona, G.; Russo, N.
On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme
J. Agric. Food Chem.
58
10768-10773
2010
Homo sapiens (P04035)
brenda
Mozzicafreddo, M.; Cuccioloni, M.; Eleuteri, A.; Angeletti, M.
Rapid reverse phase-HPLC assay of HMG-CoA reductase activity
J. Lipid Res.
51
2460-2463
2010
Homo sapiens
brenda
Pak, V.V.; Koo, M.; Kwon, D.Y.; Yun, L.
Design of a highly potent inhibitory peptide acting as a competitive inhibitor of HMG-CoA reductase
Amino Acids
43
2015-2025
2012
Homo sapiens
brenda
Oliveira, E.F.; Cerqueira, N.M.F.S.A.; Ramos, M.J.; Fernandes, P.A.
QM/MM study of the mechanism of reduction of 3-hydroxy-3-methylglutaryl coenzyme A catalyzed by human HMG-CoA reductase
Catal. Sci. Technol.
6
7172-7185
2016
Homo sapiens (P04035)
-
brenda
Costa, C.H.S.; Oliveira, A.R.S.; Dos Santos, A.M.; da Costa, K.S.; Lima, A.H.L.E.; Alves, C.N.; Lameira, J.
Computational study of conformational changes in human 3-hydroxy-3-methylglutaryl coenzyme reductase induced by substrate binding
J. Biomol. Struct. Dyn.
37
4374-4383
2019
Homo sapiens (P04035), Homo sapiens
brenda
Ando, H.; Horibata, Y.; Aoyama, C.; Shimizu, H.; Shinohara, Y.; Yamashita, S.; Sugimoto, H.
Side-chain oxysterols suppress the transcription of CTP phosphoethanolamine cytidylyltransferase and 3-hydroxy-3-methylglutaryl-CoA reductase by inhibiting the interaction of p300 and NF-Y, and H3K27 acetylation
J. Steroid Biochem. Mol. Biol.
195
105482
2019
Homo sapiens (P04035), Mus musculus (Q01237)
brenda
EXTERNAL LINKS (specific for EC-Number 1.1.1.34)
Transporter Classification Database (TCDB): 2.A.6.6.5, 2.A.6.6.10
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
